Document:

Exhibit 10.12

 

THIS SIXTH AMENDED AND RESTATED SECURED
CONVERTIBLE PROMISSORY NOTE AND ANY SECURITIES INTO WHICH THIS SIXTH AMENDED AND RESTATED SECURED CONVERTIBLE PROMISSORY NOTE IS
CONVERTIBLE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION
OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

THIS SIXTH AMENDED AND RESTATED SECURED
CONVERTIBLE PROMISSORY NOTE AND ANY SECURITIES INTO WHICH THIS SECURED CONVERTIBLE PROMISSORY NOTE IS CONVERTIBLE ARE SUBJECT TO
RESTRICTIONS ON TRANSFER CONTAINED IN THAT CERTAIN SIXTH AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT, DATED AS OF FEBRUARY
6, 2014, BETWEEN THE COMPANY AND THE LENDER REFERENCED HEREIN, WHICH RESTRICTIONS ON TRANSFER ARE INCORPORATED HEREIN BY REFERENCE.

 

SIXTH AMENDED AND RESTATED

SECURED CONVERTIBLE PROMISSORY NOTE

 

	$560,000	February 6, 2014

 

New York, New York

 

FOR VALUE RECEIVED,
NANO VIBRONIX, INC., a Delaware corporation (the “Company”), hereby promises to pay to the order of GLOBIS CAPITAL
PARTNERS, L.P. (together with its successors, representatives, and assigns, the “Lender”), the principal sum
of FIVE HUNDRED AND SIXTY THOUSAND DOLLARS ($560,000) with interest on the outstanding principal amount at the rate, except as
otherwise provided herein, of six percent (6.00%) per annum (computed on the basis of actual calendar days elapsed and a year of
365 or 366 days, as the case may be) or, if less, at the highest rate of interest then permitted under applicable law; provided,
however, that from and after an Event of Default (as defined below), all indebtedness hereunder shall accrue interest at
the rate of ten percent (10.00%) per annum (computed on the basis of actual calendar days elapsed and a year of 365 or 366 days,
as the case may be) or, if less, at the highest rate permitted by applicable law (the “Post-Default Rate”).
Interest shall commence with the date hereof and shall continue on the outstanding principal of this Sixth Amended and Restated
Secured Convertible Promissory Note (this “Note”) until paid or converted in accordance with the provisions
hereof.

 

Reference is made to
the Sixth Amended and Restated Securities Purchase Agreement of even date herewith by and between the Company and the Lender, as
the “Investor” (the “Agreement”), which amends and restates the Existing SPA (as defined
in the Agreement). In connection with the Existing SPA, the Company issued to the Lender that certain Fifth Amended and Restated
Secured Convertible Promissory Note dated December 9, 2013 in the principal amount of $480,000 (the “Existing Note”).
The Company and the Lender desire to amend and restate the Existing SPA and the Existing Note to increase the principal amount
outstanding hereunder.

 

    	 

    	 

    

 

Reference is also made
to the Sixth Amended and Restated Securities Purchase Agreement of even date herewith by and between the Company and Globis Overseas
Fund Ltd. (the “Overseas SPA”). In connection with the Overseas SPA, the Company issued to Globis Overseas Fund
Ltd. that certain Sixth Amended and Restated Secured Convertible Promissory Note dated February 6, 2014 in the principal amount
of $140,000 (the “Overseas Note”).

 

1.          Definitions.
For purposes of this Note, the following terms shall have the following meanings (capitalized terms used herein but not otherwise
defined shall have the meanings provided therefor in the Agreement):

 

“Affiliate”
shall mean with respect to any Person, any other Person (i) which directly or indirectly through one or more intermediaries
Controls, or is Controlled by, or is under common Control with, such first Person, (ii) which beneficially owns or holds 10%
or more of any class of the voting stock of such first Person, or (iii) whereby 10% or more of the voting stock (or in the
case of a Person which is not a corporation, 10% or more of the equity interest) of such other Person is beneficially owned or
held by such first Person or by a Subsidiary of such first Person.

 

“Agreement” shall have
the meaning ascribed to such term in the recitals of this Note.

 

“Business
Day” means any day which is not a Saturday or Sunday or a legal holiday on which banks are authorized or required to
be closed in New York, New York.

 

“Collateral”
shall have the meaning ascribed to such term in Section 2 of this Note.

 

“Common Stock”
means the common stock of the Company.

 

“Common Stock
Equivalent” means any Convertible Security or warrant, Option or other right to subscribe for or purchase any Additional
Shares of Stock or any Convertible Security.

 

“Control”
shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies
of a person, whether through the ownership of voting securities, by contract or otherwise, and the terms “Controlling”
and “Controlled” (and the lower-case versions of the same) shall have meanings correlative thereto.

 

“Convertible
Securities” shall mean evidences of indebtedness, shares of stock or other securities or instruments (other than Options)
which are convertible into or exchangeable for shares of Common Stock, either immediately or upon the arrival of a specified date
or the occurrence of a specified event.

 

“Debt”
shall mean, with respect to any Person, all liabilities, obligations and indebtedness of such Person of every kind and nature,
including, without limitation: (i) indebtedness or liability for borrowed money, or for the deferred purchase price of property
or services (including trade obligations); (ii) obligations as lessee under any leases (including under any capital leases); (iii)
any reimbursement or other obligations under any performance or surety bonds or any letters of credit issued for the account of
such Person; (iv) all net obligations in respect of any derivative products; (v) all guaranties, endorsements (other than for collection
or deposit in the ordinary course of business), and other contingent obligations to purchase, to provide funds for payment, to
supply funds to invest in any other Person, or otherwise to assure a creditor against loss; and (vi) obligations secured by any
Lien on property owned by such Person, whether or not the obligations have been assumed.

 

“Default”
means an Event of Default or an event or condition which with notice or lapse of time or both would constitute an Event of Default.

 

“Exercise
Price” shall have the meaning ascribed to such term in Section 5(a) of this Note

 

    	2

    	 

    

 

“Fundamental
Transaction” means that (i) the Company or any of its subsidiaries shall, directly or indirectly, in one or more related
transactions, (1) consolidate or merge with or into (whether or not the Company or any of its subsidiaries is the surviving corporation)
any other Person, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its
respective properties or assets to any other Person, or (3) allow any other Person to make a purchase, tender or exchange offer
that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Company (not including any shares
of Voting Stock of the Company held by the Person or Persons making or party to, or associated or affiliated with the Persons making
or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other
Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Company (not including
any shares of Voting Stock of the Company held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (5) reorganize,
recapitalize or reclassify the Common Stock, or (ii) any “person” or “group” (as these terms are used for
purposes of Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and
outstanding Voting Stock of the Company.

 

“GAAP”
means generally accepted principles of good accounting practice in the United States, consistently applied.

 

“Governmental
Authority” shall mean any federal, state, local or other governmental department, commission, board, bureau, agency or
other instrumentality or authority, domestic or foreign, exercising executive, legislative, judicial, regulatory or administrative
authority or functions of or pertaining to government.

 

“Lien”
shall mean any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory
or other), claim or other priority or preferential arrangement of any kind or nature whatsoever (other than a financing statement
filed by a lessor in respect of an operating lease not intended as security).

 

“Material
Adverse Effect” shall mean (i) a material and adverse effect on the legality, validity or enforceability of any
Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, condition (financial
or otherwise) or prospects of the Company and its direct or indirect Subsidiaries, taken as a whole on a consolidated basis, or
(iii) a material and adverse impairment of the Company’s ability to perform fully on a timely basis its obligations
under any of the Transaction Documents to which such Person is party.

 

“Obligations”
shall mean all obligations of the Company to the Lender howsoever created, arising or evidenced, whether direct or indirect, joint
or several, absolute or contingent, or now or hereafter existing, or due or to become due, which arise out of or in connection
with this Note and the other Transaction Documents, including all costs and expenses incurred by the Lender in connection with
the enforcement of this Note or any other Transaction Document.

 

“Options”
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

“Patents”
shall have the meaning ascribed to such term in Section 2 of this Note.

 

    	3

    	 

    

 

“Permitted
Debt” shall mean, with respect to the Company and each of its direct and indirect Subsidiaries, any of (i) the Obligations,
(ii) trade accounts payable incurred in the ordinary course which are due no later than 90 calendar days after invoice, (iii) other
current liabilities incurred in the ordinary course of business and not incurred through the borrowing of money or the obtaining
of credit, (iv) obligations under long-term real property leases incurred in the ordinary course of business, (v) short-term lease
obligations or indebtedness incurred to finance the cost of tangible personal property (which was acquired after the date hereof)
in an amount that does not exceed an aggregate of $10,000 during any twelve month period, (vi) Debt in respect of taxes or other
governmental charges which is not yet due or which is being contested in good faith by appropriate proceedings, and (vii) Debt
in connection with the Overseas Note.

 

“Permitted
Lien” shall mean, as of any particular time with respect to the Company and each of its direct and indirect Subsidiaries,
(i) Liens of taxes, assessments or other charges of a Governmental Authority not then delinquent or which are being contested in
good faith by appropriate proceedings, (ii) Liens in favor of the Lender created pursuant to the Transaction Documents, (iii) any
mechanic’s, worker’s, repairer’s, supplier’s, vendor’s or like Liens securing obligations arising
in the ordinary course of business (A) that are not mature and overdue, (B) that do not materially impair the value of the Collateral
provided to the Lender pursuant to the Transaction Documents and (C) that could not result in an aggregate liability in excess
of $10,000, (iv) Liens arising solely by virtue of any statutory or common law provision relating to banker’s liens, rights
of set-off or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution,
provided that such deposit account is not a dedicated cash collateral account.

 

“Person”
shall mean an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust,
a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

 

“Subsidiary”
shall mean, with respect to any Person (herein referred to as the “parent”), any corporation, limited liability company,
partnership, association or other business entity (i) of which securities of other ownership interests representing more than 50%
of the equity or more than 50% of the ordinary voting power or more than 50% of the general partnership interests are, at the time
any determination is being made, owned, controlled or held by the parent, or (ii) that is, at any time any determination is made,
otherwise Controlled by, the parent or one or more Subsidiaries of the parent and one or more Subsidiaries of the parent.

 

“UCC”
means the Uniform Commercial Code as the same may, from time to time, be in effect in the State of New York.

 

“Voting Stock”
of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have the general voting
power to elect, or the general power to appoint, at least a majority of the board of directors, managers or trustees of such Person
(irrespective of whether or not at the time capital stock of any other class or classes shall have or might have voting power by
reason of the happening of any contingency).

 

2.          Grant
of Security Interest. As collateral security for the prompt and complete payment and performance of all of the Company’s
present or future Obligations, the Company hereby grants a security interest and mortgage to the Lender, as security, in and to
the Company’s entire right, title and interest in, to and under the following intellectual property, now owned or hereafter
acquired by the Company or in which the Company now holds or hereafter acquires any interest (all of which shall collectively be
called the “Collateral” for purposes of this Note):

 

    	4

    	 

    

 

(a)          All
letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings
thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country,
including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in
any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part
or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications,
including without limitation the patents and patent applications set forth on Exhibit “A” attached hereto (collectively,
the “Patents”);

 

(b)          Any
and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right,
but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified
above;

 

(c)          All
licenses or other rights to use any of the Patents, and all license fees and royalties arising from such use to the extent permitted
by such license or rights;

 

(d)          All
amendments, renewals and extensions of any of the Patents; and

 

(e)          All
proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing.

 

3.           Maturity.
Unless sooner paid or converted in accordance with the terms hereof, the entire unpaid principal amount and all unpaid accrued
interest shall become fully due and payable on the earlier of (a) April 30, 2014, (b) the closing date of a financing, conducted
through a bona fide arm’s length transaction, in which the Company (i) issues and sells for cash its capital stock to investor(s)
and/or (ii) issues indebtedness to lenders, in aggregate amount from the date hereof equal to or greater than Two Hundred and Fifty
Thousand Dollars ($250,000), or (c) the date of the acceleration of the maturity of this Note by the Lender upon the occurrence
of an Event of Default (such earlier date, the “Maturity Date”).

 

4.           Payments.

 

(a)          Form
of Payment. All payments of interest and principal (other than payment by way of conversion) shall be in lawful money of the
United States of America to the Lender, at the address specified in the Agreement, or at such other address as may be specified
from time to time by the Lender in a written notice delivered to the Company. All payments made hereunder shall be applied first
to accrued interest, and thereafter to principal and any fees due and owing to the Lender.

 

(b)          Prepayment.
Prepayment of principal or interest under this Note without the express prior written consent of the Lender is not permitted.

 

5.           Conversion.

 

(a)          Conversion
at the Option of the Lender. At any time prior to the Maturity Date, the Lender may, in its sole discretion and upon 5 Business
Days’ prior written notice to the Company, convert all or a portion of the Debt of the Company outstanding on such date under
this Note into that number of shares of Common Stock which is equal to the quotient obtained by dividing (a) the sum of (i) the
outstanding principal amount of this Note elected by the Lender to be so converted and (ii) any accrued but unpaid interest thereon
elected by the Lender to be so converted by (b) $0.38 (subject to appropriate adjustments for any stock dividend, stock split,
stock combination, reclassification or similar transaction after the date hereof) (the “Exercise Price”). Any
accrued but unpaid interest not converted into shares of Common Stock as provided in the preceding sentence shall be paid in cash
on such date. Prior to the execution of this Note, the Company shall have reserved and set aside for issuance to the Lender such
number of shares of Common Stock as would be issuable upon conversion of the Note pursuant to this Section 5(a).

 

    	5

    	 

    

 

(b)          Conversion
or Repayment Upon Maturity. In the event that any Debt under this Note remains outstanding on the Maturity Date, then the principal
amount under this Note then outstanding and any accrued but unpaid interest thereon shall, at the option of the Lender, either
(a) become immediately due and payable on such date or (b) convert on such date into that number of shares of Common Stock which
is equal to the quotient obtained by dividing (i) the sum of (A) the then outstanding principal amount of this Note elected by
the Lender to be so converted and (B) any accrued but unpaid interest thereon elected by the Lender to be so converted by (ii)
$0.38 (subject to appropriate adjustments for any stock dividend, stock split, stock combination, reclassification or similar transaction
after the date hereof). Any principal and any accrued but unpaid interest not converted into shares of Common Stock as provided
in the preceding sentence shall be paid in cash on the Maturity Date. Prior to the execution of this Note, the Company shall have
reserved and set aside for issuance to the Lender such number of shares of Common Stock as would be issuable upon conversion of
the Note pursuant to this Section 5(b).

 

(c)          Issuance
of Certificates. As soon as is reasonably practicable after a conversion has been effected (but in any event within five (5)
Business Days thereafter), the Company shall deliver to the Lender a certificate or certificates representing the number of shares
of Common Stock issuable by reason of such conversion in such name or names and in such denomination or denominations as the Lender
may specify.

 

(d)          No
Fractional Shares. If any fractional share of Common Stock would, except for the provisions hereof, be deliverable upon conversion
of this Note, the Company, in lieu of delivering such fractional share, shall pay an amount equal to the value of such fractional
share, as determined by the per share conversion price used to effect such conversion.

 

(e)          Issuance
Costs. The issuance of certificates for shares of capital stock issuable upon conversion of this Note shall be made without
charge to the Lender for any documentary stamp tax in respect thereof or other cost incurred by the Company in connection with
such conversion and the related issuance of such shares of Common Stock; provided, that the Company shall not be required
to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon
conversion in a name other than that of the Lender so converted and the Company shall not be required to issue or deliver such
certificates unless or until the person or persons requesting the issuance thereof shall have paid to the Company the amount of
such tax or shall have established to the satisfaction of the Company that such tax has been paid. Upon conversion of this Note,
the Company shall take all such actions as are necessary in order to ensure that the Common Stock issuable with respect to such
conversion shall be validly issued, fully paid and nonassessable.

 

(f)          Compliance
with Laws and Regulations. The Company shall take all such actions as may be necessary to assure that all shares of capital
stock issued upon conversion of this Note may be so issued without violation of any applicable law or governmental regulation or
any requirement of any domestic securities exchange upon which such shares of capital stock may be listed (except for official
notice of issuance which shall be immediately delivered by the Company upon such issuance).

 

    	6

    	 

    

 

(g)          Stock
Dividends, Subdivisions and Combinations. Without limiting any provision of this Note, if the Company, at any time after the
date hereof, (1) pays a stock dividend on one or more classes of its then outstanding shares of Common Stock or otherwise makes
a distribution on any class of capital stock that is payable in shares of Common Stock, (2) subdivides (by any stock split, stock
dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number
of shares or (3) combines (by combination, reverse stock split or otherwise) one or more classes of its then outstanding shares
of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of
which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause
(1) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution, and any adjustment pursuant to clause (2) or (3) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this paragraph
occurs during the period that an Exercise Price is used in any calculation hereunder, then in such calculation such Exercise Price
shall be adjusted appropriately to reflect such event.

 

(h)          Issuance
of Additional Shares of Stock. In the event the Company shall at any time following the date hereof issue or sell any share
of Common Stock (otherwise than as provided in Section 5(g) hereof or pursuant to Common Stock Equivalents granted or issued prior
to the date hereof) (an “Additional Share of Stock”) at a price per share less than the Exercise Price then
in effect, or without consideration (in which case such Additional Shares of Stock shall be deemed to have been issued at a price
per share of $0.001 per share), the Exercise Price then in effect upon each such issuance shall be decreased to the price equal
to the consideration per share paid for such Additional Share of Stock.

 

(i)          Issuance
or Modification of Common Stock Equivalents. In the event the Company shall, at any time following the date hereof: (1) issue
or sell any Common Stock Equivalent with an exercise or conversion price less than the Exercise Price then in effect, or (2) modify
the conversion or exercise price of any Common Stock Equivalent issued prior to, on or after the date hereof, to an exercise or
conversion price less than the Exercise Price then in effect, the Exercise Price then in effect shall be decreased to the exercise
or conversion price of such Common Stock Equivalent.

 

(j)          Certain
Issues Excepted. Anything herein to the contrary notwithstanding, the Company shall not be required to make any adjustment
to the Exercise Price pursuant to Sections 5(h) or 5(i) hereof upon (1) securities issued (other than for cash) in connection with
a merger, acquisition, or consolidation, (2) securities issued pursuant to the exercise or conversion of Common Stock Equivalents
issued prior to the date hereof (but such exception shall not affect the obligation to decrease the Exercise Price if required
by Section 5(i)(2) hereof), (3) securities issued in connection with bona fide strategic license agreements or other partnering
arrangements so long as such issuances are not for the purpose of raising capital and (4) Common Stock issued or options to purchase
Common Stock granted, in each case, pursuant to the Company’s stock option plans and employee stock purchase plans that have
been approved for adoption by the Company’s board of directors and stockholders.

 

(k)          Fundamental
Transactions. Prior to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common Stock
are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate
Event”), the Company shall make appropriate provision to insure that the Lender will thereafter have the right to receive
upon conversion of this Note at any time after the consummation of the applicable Fundamental Transaction but prior to the repayment
in full of this Note, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) issuable
upon the conversion of this Note prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any
other property whatsoever (including warrants or other purchase or subscription rights) which the Lender would have been entitled
to receive upon the happening of the applicable Fundamental Transaction had this Note been converted immediately prior to the
applicable Fundamental Transaction (without regard to any limitations on the conversion of this Note). Provision made pursuant
to the preceding sentence shall be in a form and substance reasonably satisfactory to the Lender. The provisions of this Clause
(k) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.

 

    	7

    	 

    

  

6.           Affirmative
Covenants. So long as any Obligations remain outstanding, the Company shall:

 

(a)          Compliance
with Laws. Comply in all material respects with applicable laws, rules, regulations and orders, such compliance to include,
without limitations, paying before the same become delinquent all taxes, assessments, and charges imposed upon it or upon its property
by any Governmental Authority except for good faith contests for which adequate reserves are being maintained.

 

(b)          Information.
Deliver to the Lender or cause to be delivered to the Lender, in form and detail satisfactory to Lender, the following financial
and other information:

 

(i)          written
notice of any of the following, promptly, and in any event within three (3) days after the Company actually becomes aware of any
of the following: (i) any proceeding being instituted or threatened by or against it involving a sum in excess of $25,000 in the
aggregate for all proceedings, (ii) any order, judgment or decree being entered against the Company or any of its properties or
assets involving a sum in excess of $25,000 in the aggregate for all such orders, judgments and decrees taken together, and (iii)
any actual or prospective change, development or event which has had or could reasonably be expected to have a Material Adverse
Effect; and

 

(ii)         such
other statements, lists of property and accounts, budgets, forecasts, projections, reports, or other information as the Lender
may from time to time reasonably request.

 

(c)          Notice
of Litigation. Provide to the Lender promptly after the commencement thereof, notice of all actions, suits, and proceedings
before any court or Governmental Authority affecting the Company, which, if determined adversely to the Company, could have a Material
Adverse Effect.

 

(d)          Notice
of Defaults and Events of Defaults. Provide to the Lender, as soon as possible and in any event within three (3) days after
the occurrence thereof, with written notice of each event which either (i) is an Event of Default, or (ii) with the giving
of notice or lapse of time or both would constitute an Event of Default, in each case setting forth the details of such event and
the action which is proposed to be taken by the Company with respect thereto.

 

(e)          Governmental
Approvals. Use commercially reasonable efforts to promptly obtain and maintain any and all authorizations, consents, approvals,
licenses, franchises, concessions, leases, rulings, permits, certifications, exemptions, filings or registrations by or with any
Governmental Authority necessary for the Company to conduct its business and own (or lease) its properties or to execute, deliver
and perform the Transaction Documents, except where the failure to do so could not reasonably be expected to result in a Material
Adverse Effect.

 

(f)          Insurance.
Promptly obtain and maintain in full force and effect at all times with responsible insurance companies such insurance covering
its assets and properties, in such amounts and against such risks and with such deductibles as an enterprise conducting a similar
business under similar business conditions as the Company would customarily maintain, except where the failure to do so could not
reasonably be expected to result in a Material Adverse Effect.

 

    	8

    	 

    

 

(g)          Continuance
of Business. Maintain its legal existence, licenses and privileges in good standing under and in compliance with all applicable
laws and continue to operate the business currently conducted by the Company and its Subsidiaries. Without limiting the generality
of the foregoing, the Company shall do and cause to be done all things necessary to apply for, preserve, maintain and keep in full
force and effect all of its registrations of trademarks, service marks and other marks, trade names and other trade rights, patents,
copyrights and other intellectual property in accordance with prudent business practices.

 

(h)          Taxes.
Pay and discharge (i) all federal and other material taxes, fees, assessments and governmental charges or levies imposed upon
it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful claims for labor, materials
and supplies which, if unpaid, might become a Lien (other than a Permitted Lien) upon any of its properties or assets; and (ii) all
other lawful claims which, if unpaid, would by law become a Lien upon its property not constituting a Permitted Lien.

 

(i)          Additional
Patents. Following the date hereof, if the Company shall obtain rights to any new patents or otherwise acquires or becomes
entitled to the benefit of, or apply for registration of, any of the foregoing, the Company (i) shall promptly notify the
Lender thereof and (ii) hereby authorizes the Lender to modify, amend, or supplement Exhibit A and from time to time
to include any of the foregoing and make all necessary or appropriate filings with respect thereto.

 

(j)          Preservation
of Patents. The Company shall (i) prosecute diligently all applications in respect of the Patents, now or hereafter pending;
(ii) make federal applications on all of its unpatented but patentable inventions; (iii) preserve and maintain all of its material
rights in the Patents and protect the Patents from infringement, unfair competition, cancellation, or dilution by all appropriate
action necessary in the Company’s reasonable business judgment, including, without limitation, the commencement and prosecution
of legal proceedings to recover damages for infringement and to defend and preserve its rights in the Patents; and (iv) not abandon
any of the Patents necessary to the conduct of its business.

 

7.           Negative
Covenants. So long as any Obligations remain outstanding:

 

(a)          Liens.
The Company shall not, and shall not permit any of its direct or indirect Subsidiaries to, create or suffer to exist any Lien (other
than the Liens granted hereunder, under the Overseas Note and the Permitted Liens) on any assets of such Person.

 

(b)          Debt.
The Company shall not, and shall not permit any of its direct or indirect Subsidiaries to, incur any Debt other than Permitted
Debt; prepay, redeem, purchase, defease or otherwise satisfy in any manner prior to the scheduled repayment thereof any Debt (other
than amounts due in respect of this Note); or amend, modify or otherwise change the terms of any Debt (other than this Note) in
a manner which would accelerate the scheduled repayment thereof or otherwise be adverse to the interests of the Lender.

 

(c)          Sale
of Subsidiary. The Company shall not, and shall not permit any of its direct or indirect Subsidiaries to, sell, transfer, cause
to be sold or transferred, or otherwise dispose of, any interest in a Subsidiary of such Person.

 

(d)          Distributions.
The Company shall not declare or pay any dividends or make any distribution of any kind on the Company’s capital stock.

 

(e)          Amendment
of Organic Documents. The Company shall not amend, supplement, or otherwise modify any of the provisions of the Company’s
Organic Documents in a manner that would be materially adverse to the Lender.

 

    	9

    	 

    

 

(f)          Transaction
with Affiliates. The Company shall not, and shall not permit any of its direct or indirect Subsidiaries to, transfer, sell,
assign or otherwise dispose of any of its assets to any Affiliate or enter into any transaction directly or indirectly with or
for the benefit of any Affiliate unless the monetary or business consideration arising therefrom would be as advantageous to the
Company or, as applicable, such Subsidiary, as the Company or such Subsidiary would obtain in a comparable arm’s length transaction
with a Person not an Affiliate.

 

(g)         Sale
of Collateral. The Company shall not, and shall not permit any of its direct or indirect Subsidiaries to, sell, license, transfer
or otherwise dispose of any interest in any Collateral, except for licenses or sublicenses of rights in intellectual property on
a non-exclusive or other limited basis in the ordinary course of business.

 

(h)         Changes
in Business. The Company shall not enter into or engage in any business other than that carried on (or contemplated to be carried
on) as of the date hereof.

 

(i)          Accounting
Changes. The Company shall not change its fiscal year or make or permit any change in accounting policies or reporting practices,
except as permitted by GAAP.

 

8.          Use
of Proceeds. The Company shall use the proceeds from this Note solely to fund the operations of the Company in the ordinary
course of business.

 

9.          Default.

 

(a)         Events
of Default. For purposes of this Note, any of the following events which shall occur shall constitute an “Event of
Default”:

 

(i)          any
indebtedness under this Note is not paid when and as the same shall become due and payable, whether at maturity, by acceleration
or otherwise;

 

(ii)         a
default shall occur in the observance or performance of (A) any covenant, obligation or agreement of the Company contained in Sections
6, 7 or 8, or (B) any other provision of this Note, the Agreement or any Transaction Document and such default
shall continue uncured for a period of 5 days after the Company knew or should have known, exercising reasonable diligence, of
the event or circumstances giving rise to such default;

 

(iii)        any
representation, warranty or certification made by the Company herein or in the Agreement or in any certificate, report, document,
agreement or instrument delivered pursuant to any provision hereof or thereof shall prove to have been false or incorrect in any
material respect on the date or dates as of which made;

 

(iv)        the
Company shall (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of itself or any
part of its property, (B) become subject to the appointment of a receiver, trustee, custodian or liquidator for itself or
any part of its property that is not discharged or stayed within 60 days after such appointment, (C) make an assignment for
the benefit of creditors, (D)  or fail generally or admit in writing to its inability to pay its debts as they become due,
(E) institute any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization,
receivership, insolvency or other similar law affecting the rights of creditors generally, or file a petition or answer seeking
reorganization or an arrangement with creditors to take advantage of any insolvency law, or file an answer admitting the material
allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (F) become subject to any involuntary
proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency
or other similar law affecting the rights of creditors generally that is not dismissed within 60 days after commencement, or have
an order for relief entered against it in any proceeding under the United States Bankruptcy Code that is not dismissed within 60
days of entry;

 

    	10

    	 

    

 

(v)         the
Company shall (A) liquidate, wind up or dissolve (or suffer any liquidation, wind-up or dissolution), (B) suspend its operations
other than in the ordinary course of business, or (C) take any action to authorize any of the actions or events set forth
above in Section 9(a)(iv);

 

(vi)        any
final judgment or judgments for the payment of money aggregating in excess of $50,000 shall be rendered against the Company which
judgments are not, within 30 days after the entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within
45 days after the expiration of such stay; provided, however, that any judgment which is covered by insurance or
an indemnity from a credit worthy party shall not be included in calculating such amount so long as the Company provides the Lender
with a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to the
Lender) to the effect that such judgment is covered by insurance or an indemnity and the Company will receive the proceeds of such
insurance or indemnity within 30 days of the issuance of such judgment;

 

(vii)       (A)
any Debt of the Company (other than this Note) shall not be paid at its stated maturity or shall be duly declared to be or shall
become due and payable prior to the stated maturity thereof, or (B) there shall occur and be continuing any event under any agreement
or instrument relating to any such Debt, the effect of which is to cause such Debt to become due prior to its stated maturity,
or (C) the holder or holders of such Debt, or any trustee, agent or other representative on behalf of such holder or holders, shall
have demanded or required, pursuant to the terms of any agreement or instrument relating to such Debt, that the Company redeem,
repurchase or otherwise acquire or retire such Debt for value at any time prior to its stated maturity;

 

(viii)      the
occurrence or existence of any event or condition that, in the Lender’s reasonable and good faith judgment, has had or would
have or result in a Material Adverse Effect;

 

(ix)         any
material impairment in the value of the Collateral or the priority of the Lender’s Lien hereunder;

 

(x)          any
levy upon, seizure or attachment of a material portion of the Collateral which shall not have been rescinded or withdrawn within
20 days after the date of such levy, seizure or attachment; or

 

(xi)         (A)
the Company asserts that any Transaction Document is invalid or unenforceable, in whole or in part, or (B) the Lender shall cease
to have a perfected Lien in any of the Collateral (subject to Permitted Liens).

 

(b)          Consequences
of Events of Default.

 

(i)          Upon
the occurrence of any Event of Default, the Lender may declare any of the Obligations to be immediately due and payable and shall
have, in addition to all other rights and remedies granted to it in this Agreement or any other Transaction Document, all rights
and remedies of a secured party under the UCC and other applicable laws. Without limiting the generality of the foregoing, (w)
the Lender may, subject to the UCC and other applicable law, peaceably and without notice enter any premises of the Company, take
possession of any of the Collateral, remove or dispose of all or part of the Collateral on any premises of the Company or elsewhere,
and otherwise collect, receive, appropriate and realize upon all or any part of the Collateral, and demand, give receipt for, settle,
renew, extend, exchange, compromise, adjust, or sue for all or any part of the Collateral, as the Lender may determine; (x) the
Lender may require the Company to assemble all or any part of the Collateral and make it available to the Lender at any place and
time designated by the Lender; (y) the Lender may secure the appointment of a receiver of the Collateral or any part thereof (to
the extent and in the manner provided by applicable law); (z) the Lender may sell, resell, lease, use, assign, license, sublicense,
transfer or otherwise dispose of any or all of the Collateral in its then condition or following any commercially reasonable preparation
or processing (utilizing in connection therewith any of the Company’s assets, without charge or liability to the Lender therefor)
at public or private sale, by one or more contracts, in one or more parcels, at the same or different times, for cash or credit,
or for future delivery without assumption of any credit risk, all as the Lender deems advisable; provided, however, that
the Company shall be credited with the net proceeds of sale only when such proceeds are finally collected by the Lender.

 

    	11

    	 

    

  

(ii)         For
the purpose of enabling the Lender to exercise its rights and remedies under this Section 9 during the continuance of an Event
of Default, the Company hereby grants to the Lender an irrevocable, non-exclusive and assignable license (exercisable without payment
or royalty or other compensation to the Company) to use, license or sublicense any intellectual property Collateral.

 

(iii)        The
Lender has no obligation to attempt to satisfy the Obligations by collecting them from any other Person liable for them, and the
Lender may release, modify or waive any Collateral provided by any other Person to secure any of the Obligations, all without affecting
the Lender’s rights against the Company. The Company waives any right it may have to require the Lender to pursue any third
Person for any of the Obligations. The Lender may comply with any applicable state or federal law requirements in connection with
a disposition of the Collateral and compliance will not be considered adversely to affect the commercial reasonableness of any
sale of the Collateral. The Lender may sell the Collateral without giving any warranties as to the Collateral. The Lender may specifically
disclaim any warranties of title or the like. This procedure will not be considered adversely to affect the commercial reasonableness
of any sale of the Collateral. If the Lender sells any of the Collateral upon credit, the Company will be credited only with payments
actually made by the purchaser, received by the Lender and applied to the indebtedness of the purchaser. In the event the purchaser
fails to pay for the Collateral, the Lender may resell the Collateral and the Company shall be credited with the proceeds of the
sale.

 

(iv)        The
cash proceeds actually received from the sale or other disposition or collection of Collateral, and any other amounts received
in respect of the Collateral the application of which is not otherwise provided for herein, shall be applied first, to the payment
of the reasonable costs and expenses of the Lender in exercising or enforcing its rights hereunder and in collecting or attempting
to collect any of the Collateral, and to the payment of all other amounts payable to the Lender; and second, to the payment of
the Obligations. Any surplus thereof which exists after payment and performance in full of the Obligations shall be promptly paid
over to the Company or otherwise disposed of in accordance with the UCC or other applicable law. The Company shall remain liable
to the Lender for any deficiency which exists after any sale or other disposition or collection of Collateral.

 

(v)         The
Lender shall also have any other rights which the Lender may have been afforded under any contract or agreement at any time and
any other rights which the Lender may have pursuant to applicable law. The Lender may exercise any and all of its remedies under
this Note, the Agreement and the other Transaction Documents contemporaneously or separately from the exercise of any other remedies
hereunder or under applicable law.

 

10.         Lost,
Stolen, Destroyed or Mutilated Note. In case this Note shall be mutilated, lost, stolen or destroyed, the Company shall issue
a new Note of like date, tenor and denomination and deliver the same in exchange and substitution for and upon surrender and cancellation
of any such mutilated Note, or in lieu of any such Note lost, stolen or destroyed, upon receipt of evidence satisfactory to the
Company of the loss, theft or destruction of any such Note.

 

    	12

    	 

    

 

11.         Governing
Law. This Note is to be construed in accordance with and governed by the laws of the State of New York. The provisions of Section
5.3 of the Agreement relating to venue, submission to jurisdiction and the waiver of the right to jury trial are by this reference
incorporated herein, mutatis mutandis, as if set forth herein in full.

 

12.         Amendment
and Waiver. Any term of this Note may be amended and the observance of any term of this Note may be waived (either generally
or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Lender.

 

13.         Notices.
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Note
shall be made in accordance with Section 5.6 of the Agreement.

 

14.         Securities
Purchase Agreement. This Note is issued pursuant to the terms of the Agreement.

 

15.         Termination.
Upon payment and performance in full of all Obligations, the security interest created under this Note shall terminate.

 

16.         Authorization.
The Company hereby irrevocably authorizes the Lender (or its designee) at any time and from time to time to file in any jurisdiction
any financing or continuation statement and amendment thereto or any registration of charge, mortgage or otherwise, containing
any information required under the UCC or any applicable of any other applicable jurisdiction (in each case, without the signature
of the Company to the extent permitted by applicable law), reasonably necessary or appropriate in the judgment of the Lender to
perfect or evidence its first priority security interest in and Lien on the Collateral. The Company hereby irrevocably ratifies
and approves any such filing, registration or recordation in any jurisdiction by the Lender (or its designee) that has occurred
prior to the date hereof, of any financing statement, registration of charge, mortgage or otherwise. The Company agrees to provide
to the Lender (or its designee) any and all information required under the UCC or any applicable law of any other applicable jurisdiction
for the effective filing of a financing statement and any amendment thereto or any registration of charge, mortgage or otherwise
in connection with the Collateral.

 

17.         Severability.
If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from
this Note and the balance of this Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.

 

18.         Assignment.
The Company shall not have the right to assign its rights and obligations hereunder or any interest herein. The Lender may at any
time assign or transfer all or part of its rights and/or obligations under this Note.

 

19.         Remedies
Cumulative; Failure or Indulgence Not a Waiver. The remedies provided in this Note shall be cumulative and in addition to all
other remedies available under this Note and any of the other Transaction Documents. No failure or delay on the part of the Lender
in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise
of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

 

    	13

    	 

    

 

20.         Payments.
Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, such payment shall be made in lawful
money of the United States of America by a check drawn on the account of the Company and sent via overnight courier service to
such Person at such address as previously provided to the Company in writing (which address, in the case of the Lender as of the
date of issuance hereof, shall initially be the address for the Lender as set forth in the Agreement); provided that the
Lender may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior
written notice setting out such request and the Lender’s wire transfer instructions. Whenever any payment to be made shall
otherwise be due on a day which is not a Business Day, such payment shall be made on the immediately succeeding Business Day and
such extension of time shall be included in the computation of accrued interest. All payments received by the Lender after 5:00
p.m. shall be deemed received on the next succeeding Business Day and any applicable interest shall continue to accrue.

 

21.         Excessive
Interest. Notwithstanding any other provision herein to the contrary, this Note is hereby expressly limited so that the interest
rate charged hereunder shall at no time exceed the maximum rate permitted by applicable law. If, for any circumstance whatsoever,
the interest rate charged exceeds the maximum rate permitted by applicable law, the interest rate shall be reduced to the maximum
rate permitted, and if the Lender shall have received an amount that would cause the interest rate charged to be in excess of the
maximum rate permitted, such amount that would be excessive interest shall be applied to the reduction of the principal amount
owing hereunder (without charge for prepayment) and not to the payment of interest, or if such excessive interest exceeds the unpaid
balance of principal, such excess shall be refunded to the Company.

 

22.         Facsimile
Transmission of Signature Page. The delivery of any executed signature page to this Note by telecopy or other electronic imaging
means shall be effective as delivery of a manually executed signature page to this Note.

 

23.         Amendment
and Restatement. The Company and the Lender agree that: (a) the Obligations represent, among other things, the restatement,
renewal, amendment and modification of the “Obligations” (as defined in the Existing Note); (b) this Note is intended
to, and does hereby, restate, renew, amend, modify, supersede and replace the Existing Note in its entirety; and (c) the entering
into and performance by the Company and the Lender of their respective obligations under the Transaction Documents and the transactions
evidenced hereby and thereby do not constitute a novation nor shall they be deemed to have terminated, extinguished or discharged
the indebtedness under the Existing Note, all of which indebtedness shall continue under and be governed by this Note. All references
in the other Transaction Documents to the Existing Note shall henceforth include references to this Note, as may, from time to
time, be further amended, modified, extended, and/or renewed. To the extent permitted by applicable Law, any and all of the terms
and provisions of the other Transaction Documents are hereby amended and modified wherever necessary, even though not specifically
addressed herein, so as to conform to the amendments and modifications set forth herein.

 

24.         Ratifications.
The Company hereby (a) ratifies and confirms all provisions of the other Transaction Documents, and (b) ratifies and confirm that
all guaranties, assurances, and liens granted, conveyed, or assigned to the Lender under the Existing Note are not released, reduced,
or otherwise adversely affected by this Note and continue to guarantee, assure, and secure full payment and performance of the
present and future obligations of the Company under this Note and the Transaction Documents. The Company hereby acknowledges that
immediately prior to the execution and delivery of this Note, the outstanding principal balance of the Existing Note is $480,000
and the accrued but unpaid interest thereon is $4,655.34, which amount is and shall be payable in accordance with the terms hereof
and is in addition to the interest that accrues under this Note after the date hereof.

 

    	14

    	 

    

 

25.         Waiver
of Notice. To the extent permitted by law, the Company hereby waives demand, notice, protest and all other demands and notices
in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Transaction Documents. In
addition, the Company hereby waives, to the fullest extent permitted by law, (a) any right of redemption with respect to the Collateral,
whether before or after sale hereunder, and all rights, if any, of marshalling of the Collateral or other collateral or security
for the Obligations; (b) any right to require the Lender (i) to proceed against any Person, (ii) to exhaust any other collateral
or security for any of the Obligations, or (iii) to pursue any remedy in the Lender’s power; and (c) all claims, damages,
and demands against the Lender arising out of the repossession, retention, sale or application of the proceeds of any sale of the
Collateral.

 

(Remainder of
page intentionally left blank; signature page follows) 

 

    	15

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Sixth Amended and Restated Secured Convertible Promissory Note to be duly executed by its officers,
thereunto duly authorized as of the date first above written.

 

	Address of the Company:	NANO VIBRONIX, INC.
	 	 	 
	105 Maxess Road, Suite S124 	By:	/s/ Harold Jacob
	Melville, NY  11747	 	 
	Attn: ____________	Name:	Harold Jacob
	 	 	 
	 	Its:	Chief Executive Officer

 

	Address of the Lender:	GLOBIS CAPITAL PARTNERS, L.P.
	805 Third Avenue, 15th Floor	 	 
	New York, NY 10022	 	 
	 	By:	/s/ Paul Packer
	 	 	 
	 	Name:	Paul Packer
	 	 	 
	 	Its:	Managing Member of the General Partner 

  

    	 

    	 

    

 

Exhibit A to

 

Secured Convertible Promissory Note

 

Important Notes:

Nanovibronix strategy was to create strong IP barrier for other
companies. Nanovibronix aimed to cover it's novel technology and devices world wide, because our attempts were to create valuable
company. The author of all ideas – Jona Zumeris, D.Sc. Nanovibronix is working with Pearl Cohen Zedek and Malina patent offices.
Annuity is being done through Dennemeyer&Co

 

	Exact Legal

Name of Owner	 	Description of

Intellectual

Property	 	Country(ies)

of

Registration	 	Application or

Registration

Number(s)	 	Registration

Office(s)	 	Application or

Registration

Date(s)
	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	USA	 	7,393,501 B2	 	USA	 	
        filed May28,2003

        reg.

        Jul1,2008

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	China	 	ZL03818327.7	 	China	 	
        Filed May29,2003

        Grant

        April29,2009

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	Israel	 	165422	 	Israel	 	
        filed May28,2003

        reg.

        Aug18,2010

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters 	 	Japan	 	4504183	 	Japan	 	
        filed May28,2003

        reg.

        Apr.30,2010

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	India	 	246351	 	India	 	
        filed May29,2003

        reg.

        Feb24,2011,

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	Australia	 	2003231892	 	Australia	 	
        filed May28,2003

        reg.

        Nov6,2008

	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	European Union	 	1511414 B	 	
        European Union

        (UK,Gr,Fr)
	 	
        Filed Dec9,2004

        Grant

        Aug8,2012

 

    	 

    	 

    

 

	Exact Legal

Name of Owner	 	Description of

Intellectual

Property	 	Country(ies)

of

Registration	 	Application or

Registration

Number(s)	 	Registration

Office(s)	 	Application or

Registration

Date(s)
	Nano Vibronix, Inc.	 	Method, apparatus and system for treating biofilms associated with catheters	 	Hong Kong	 	Appl.nr 05107834.0	 	Hong Kong	 	Allowed, but decision to abandon
	Nano Vibronix, Inc.	 	Acoustic add-on device for biofilm prevention in urinary catheter	 	USA	 	7,829.029 B2	 	USA	 	
        filed May29,2007

        reg.

        Nov9,2010

	Nano Vibronix, Inc.	 	Acoustic add-on device for biofilm prevention in urinary catheter	 	China	 	Appl.nr. 200780019732.3	 	China	 	
        filed May29,2007

        allowed

	Nano Vibronix, Inc.	 	Acoustic add-on device for biofilm prevention in urinary catheter	 	European Union	 	Appl.nr 07736150.9	 	
        European Union

        (Fr,UK,Gr)
	 	
        filed Mar29,2007

        allowed

	Nano Vibronix, Inc.	 	System and method for SAW treatment of medical devices	 	USA	 	US nr. 11/710,616	 	USA	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	USA	 	US nr. 11/710,615	 	USA	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	India	 	 	 	India	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	Hong Kong	 	Appl.nr 09110611.9	 	Hong Kong	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	European Union	 	
        Appl.nr.

        07861247.0
	 	European Union	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	Canada	 	Appl.nr 2,643,423	 	Canada	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	China	 	Appl.nr. 2007/780014875.5	 	China	 	Filed Feb26,2007

 

    	 

    	 

    

 

	Exact Legal

Name of Owner	 	Description of

Intellectual

Property	 	Country(ies)

of

Registration	 	Application or

Registration

Number(s)	 	Registration

Office(s)	 	Application or

Registration

Date(s)
	Nano Vibronix, Inc.	 	System and method for surface acoustic waves treatment of skin	 	Israel	 	Appl.nr.193600	 	Israel	 	Filed Feb26,2007
	Nano Vibronix, Inc.	 	Method for friction reduction in medical tubing and applications using this method	 	USA	 	
        US nr.

        13/521,060
	 	USA	 	Filled Jul09,2012
	Nano Vibronix, Inc. (Assignment from inventors to Nano Vibronix, Inc. has not yet been recorded.  Each inventor to this patent is obligated per their employment agreement to assign these rights to NanoVibronix, Inc.)	 	Nanovibration coating process for medical devices using multi vibration modes of thin piezo element	 	USA	 	7,892,191	 	USA	 	
        filed May18,2005

        reg.

        Feb22,2011

	Nano Vibronix, Inc.	 	Nanovibration coating process for medical devices using multi vibration modes of thin piezo element	 	Russia	 	2419395	 	Russia	 	
        filed May18,2005

        reg.

        May27,2011

	Nano Vibronix, Inc.	 	Nanovibration coating process for medical devices using multi vibration modes of thin piezo element	 	European Union	 	
        Appl.nr.

        05752180.9
	 	European Union	 	
        filed May18,2005

         

	Nano Vibronix, Inc.	 	Nanovibration coating process for medical devices using multi vibration modes of thin piezo element	 	Japan	 	Appl..nr 2007-527384	 	Japan	 	
        filed May18,2005

         

 

    	 

    	 

    

 

	Exact Legal

Name of Owner	 	Description of

Intellectual

Property	 	Country(ies)

of

Registration	 	Application or

Registration

Number(s)	 	Registration

Office(s)	 	Application or

Registration

Date(s)
	Nano Vibronix, Inc.	 	Nanovibration coating process for medical devices using multi vibration modes of thin piezo element	 	Israel	 	Appl.nr. 179372	 	Israel	 	
        filed May18,2005

         

	Nano Vibronix, Inc. ( under licensing agreement with Piezo top)	 	A system and method for detection of motion	 	USA	 	6,964,640 B2	 	USA	 	
        filed Jan22,2003

        reg.

        Nov.15, 2005

	Nano Vibronix, Inc. ( under licensing agreement with Piezo top)	 	A system and method for detection of fetal heartbeat	 	USA	 	6,454,716 B1	 	USA	 	
        filed May23,2000

        reg.

        Sep24,2002

	Nano Vibronix, Inc. ( under licensing agreement with Piezo top)	 	Apparatus for sterilizing a liquid with focused acoustic standing waves	 	USA	 	7,431,892 B2	 	USA	 	
        filed Sep.25,2002

        reg.

        Oct7, 2008

	Nano Vibronix, Inc. ( under licensing agreement with Piezo top)	 	System and method for sterilization of a liquid	 	USA	 	Appl.nr. 12/188,302	 	USA	 	Filled Aug8,2008Exhibit 10.79

 

Note: Portions of this document have been marked “[c.i.]”
to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions
have been submitted separately with the Securities and Exchange Commission.

 

EXCLUSIVE LICENSE AND TECHNOLOGY TRANSFER
AGREEMENT

 

This EXCLUSIVE LICENSE AND TECHNOLOGY TRANSFER
AGREEMENT (this “Agreement”), dated as of December 9, 2013 (the “Effective Date”), is made
by and between Advaxis Inc. (“Advaxis”), a Delaware corporation, having its principal place of business at 305
College Road East, Princeton, New Jersey, and Global BioPharma, Inc. (“Licensee”), a corporation organized under
the laws of Republic of China, having a place of business at 6F, No.10, LinSen S. Road, Taipei City, Taiwan, R.O.C. Advaxis and
Licensee are individually referred to as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, Advaxis is a research-based
clinical stage corporation having expertise in the area of biotechnology leading to the development of innovative biotechnological
products, specifically in the area of cancer immunotherapeutics; 

 

WHEREAS, Advaxis possesses certain
knowledge, know-how, trade secrets, technical information, and expertise with respect to the research and development of cancer
therapeutics;

 

WHEREAS, Licensee is engaged in the
business of the development of cancer immunotherapeutics for the treatment of certain cancers and infectious diseases in the Territory
(defined below), including, but not limited to the development of vaccines, biologics and immune cell biotechnological products
and possesses related know-how and trade secrets;

 

WHEREAS, Licensee possesses certain
knowledge, know-how, trade secrets, technical and proprietary information, and expertise with respect to the research and development
of biotechnological products;

 

WHEREAS, Licensee intends to achieve
a substantial business presence in the area of biotechnological products, including but not limited to cancer and infectious disease
therapeutics, and possesses the capability to evaluate, develop, manufacture and commercialize products for uses therein;

 

WHEREAS, the Parties desire to develop,
manufacture and commercialize products relating to the prevention and treatment of Human Papillomavirus-associated diseases;

 

WHEREAS, Advaxis has filed, invented
or licensed certain patents and patent applications with respect to a platform technology which enables the design of a versatile
immunotherapy that utilizes live attenuated Listeria monocytogenes (“Lm”) bioengineered to secrete antigen/adjuvant
fusion proteins through the use of certain Lm strains that have been bioengineered to secrete a fragment of the protein
listeriolysin-O, fused to a tumor associated antigen (TAA) or other antigen of interest (“Lm-LLO Immunotherapies”)
as further described below;

 

    	 

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

WHEREAS, Licensee desires to develop
and commercialize cancer therapeutics as part of its cancer and infectious disease therapeutics business;

 

WHEREAS, Advaxis desires to grant
to Licensee certain exclusive rights and licenses relating to the Licensed Technology and Patent Rights – and the Products
which are covered by the Patent Rights – for use in the Field in the Territory, all as set forth herein, under the terms
and conditions hereinafter set forth; and

 

WHEREAS, Licensee desires to secure
rights to further develop, manufacture, use and commercialize certain products and sublicense such rights in certain territories.

 

NOW THEREFORE, in consideration of
the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, Advaxis and Licensee agree as follows:

 

ARTICLE
1

DEFINITIONS

 

As used in this Agreement, the following
terms, whether used in the singular or plural, shall have the following meanings:

 

1.1           “Advaxis
Development Expenses” shall mean (i) all out-of-pocket expenses incurred by Advaxis to Develop Products including expenses
associated with active pharmaceutical ingredients, inactive ingredients, and other raw materials, contract manufacturing site qualifications,
contract research organizations, medical writing, statistical analysis, clinical trial investigative sites, clinical trial investigator
grants and patient and/or subject costs, contract manufacturers, and clinical trial insurance, third party consultants for regulatory,
chemistry manufacturing and control, and (ii) Advaxis’s reasonable and verifiable internal research and development staff
costs of Advaxis employees working on the Development of Products (limited to Advaxis’s research and development staff and
research and development senior management salaries and associated payroll taxes and benefits excluding non-cash compensation and
bonuses) allocated to the Development of Products based on the time spent by such staff on such Development activities as compared
to other activities, but excluding any allocation of overhead and senior management compensation (other than research and development
senior management salaries and associated payroll taxes and benefits excluding non-cash compensation and bonuses).

 

1.2           “Advaxis’s
U.S. Sales” means the gross amount invoiced by Advaxis, its Affiliates or licensees to Purchasers for sale of Products
in the United States of America, less, to the extent deducted by Advaxis, its Affiliates or licensees from such gross invoice amount
the following amounts, all in accordance with GAAP:

 

(a)          trade
or cash discounts for prompt payment to the extent actually allowed;

 

(b)          promotional
allowances to the extent actually allowed;

 

(c)          price
adjustments to the extent actually allowed;

 

    	2

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(d)          amounts
accrued or actually paid for chargebacks;

 

(e)          amounts
accrued or actually paid for rebates, including any and all non-government and government rebates;

 

(f)          amounts
accrued or actually refunded due to rejected, spoiled, damaged, outdated, short dated, or returned Product;

 

(g)          sales
and other excise taxes and duties or similar governmental charges levied on such sale, to the extent such items are included in
the gross amount invoiced; and

 

(h)          freight,
shipment and transportation costs incurred in distributing Products to a Purchaser to the extent such amounts are included in the
gross amount invoiced;

 

If any Products are sold to Purchasers in
transactions that are not at arm’s length between the buyer and seller, or for consideration other than cash, then the gross
amount to be included in the calculation of Advaxis’s U.S. Sales for such sales shall be the amount that would have been
invoiced had the transaction been conducted at arm’s length, which amount shall be determined, whenever possible, by reference
to the average selling price of the relevant Product in arm’s-length transactions in the country of sale at the time of sale.
“Purchaser” means a person or entity other than Advaxis, its Affiliates and licensees.

 

1.3           “Affiliate”
of a Party means any Person, whether de jure or de facto, which directly or indirectly controls such Party, is controlled by such
Party, or is under common control with such Party for so long as such control exists. For purposes of this definition, “control”
(including “controlled by” or “under common control with”) means the decision-making authority over another
Person and, further, such control shall be presumed to exist where a Person owns more than fifty percent (50%) of the equity (or
such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the
power to vote on or direct the affairs of another Person.

 

1.4           
“ADXS- HPV” shall mean a composition having a recombinant Listeria monocytogenes (“Lm”)
that expresses and secretes a fusion protein causing an immune response including, but not limited to, an embodiment in which such
fusion protein is comprised of an attenuated strain that is derived from the parent strain 10304S, and is attenuated primarily
by the excision of the gene prfA or other genes and which episomally expresses an antigen fusion protein comprised of the Human
Papillomavirus (“HPV”) antigen HPV16-E7 fused to a truncated and non-cytolytic fragment of the protein Listeriolysin
O (“LLO”) in which a replacement of a 1-50 amino acid peptide as set forth in SEQ ID NO. 18 for a 1-50 amino acid non-LLO
peptide, or a mutation of residue C484, and W492 of SEQ ID NO. 37, or a deletion of a 1-50 amino acid peptide as set forth in SEQ
ID NO. 18.

 

1.5           
“cGCP” means current Good Clinical Practices (a) as promulgated under 21 C.F.R. Parts 11, 50, 54, 56, 312, and
314, as the same may be amended or re-enacted from time to time and (b) required by law in countries other than the United States
where clinical studies are conducted.

    	3

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

1.6           “cGLP”
means current Good Laboratory Practices (a) as promulgated under 21 C.F.R. Part 58, as the same may be amended or re-enacted from
time to time and (b) as required by law in countries other than the United States where non-clinical laboratory studies are conducted.

 

1.7           “cGMP”
means current Good Manufacturing Practices (a) as promulgated under 21 C.F.R. Parts 210 and 211, as the same may be amended or
re-enacted from time to time and (b) as required by law in countries other than the United States where pharmaceutical product
manufacturing is conducted.

 

1.8           “Calendar
Quarter” means for each Calendar Year, each of the three calendar month periods
ending March 31, June 30, September 30 and December 31; provided, however, that the first calendar quarter
for the first Calendar Year shall extend from the Effective Date to December 31, 2013 and the last calendar quarter for the last
Calendar Year shall extend from the beginning of the last complete calendar quarter to the effective date of expiration or termination
of this Agreement.

 

1.9           “Calendar
Year” means, (a) for the first calendar year, the period commencing on the Effective Date and ending on December 31,
2013, (b) for each successive calendar year, the period beginning on January 1 and ending twelve (12) consecutive calendar
months later on December 31, and (c) for the calendar year in which this Agreement is terminated or expires, the period beginning
on January 1 of such calendar year and ending on the effective date of the termination or expiration of this Agreement.

 

1.10         
“Change of Control” means, with respect to any Party, the consummation of any transaction of the following events:
(a) any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more
than fifty percent (50%) of the total voting power of the stock then outstanding of such Party normally entitled to vote in elections
of directors; (b) such Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates
with or merges into such Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting
power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties
holding at least fifty percent (50%) of the outstanding shares of such Party immediately preceding such consolidation or merger;
(c) such Party conveys, transfers or leases all or substantially all of its assets to a Third Party, or (d) any other arrangement
whereby a Third Party controls or has the right to control the board of directors or equivalent governing body that has the ability
to cause the direction of the management or policies of such Party.

 

1.11         
“Commercialization” means, with respect to a Product for use in the Field in the Territory, any and all activities
directed to marketing, advertising, promoting, detailing, distributing, offering for sale and selling a Product. When used as a
verb, “Commercialize” means to engage in Commercialization.

 

    	4

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

1.12         “Commercially
Reasonable Efforts” means with respect to a Party, the efforts and resources which would be used (including the promptness
in which such efforts and resources would be applied) by that Party consistent with its normal business practices, which in no
event shall be less than the level of efforts and resources standard in the pharmaceutical industry for a company similar in size
and scope to such Party, with respect to a product or potential product at a similar stage in its Development or product life cycle
taking into account efficacy, safety, commercial value, the competitiveness of alternative products of Third Parties that are in
the marketplace, and the patent and other proprietary position of such product.

 

1.13         
“Cover”, “Covering” or “Covered” means, with respect to
a product or with respect to technology, that, in the absence of a license granted under a Valid Claim, the making, use, offering
for sale, sale, or importation of such product or the practice of such technology would infringe such Valid Claim.

 

1.14         “Development”
means non-clinical (including pre-clinical) and clinical drug development activities of ADXS-HPV and the Product, including formulation
development and optimization, stability testing, laboratory analysis and testing, toxicology studies, statistical analysis and
report writing, conducting clinical trials for the purpose of obtaining or maintaining Regulatory Approval (including post-marketing
studies) and regulatory affairs relating to ADXS-HPV and the Product. Development shall include all studies primarily intended
to support or maintain a Product label or obtain any Product labeling change. When used as a verb, “Develop” and “Developing”
mean to engage in Development.

 

1.15         “Effective
Date” has the meaning given such term on the first page of this Agreement.

 

1.16         “FDA”
means the United States Food and Drug Administration.

 

1.17         “Field”
means all present and future indications related to HPV-associated diseases.

 

1.18         “First
Commercial Sale” means the date of the first invoice for a Product to a Buyer in any country in the Territory for commercial
use in the Field.

 

1.19         “GAAP”
shall mean United States generally accepted accounting principles consistently applied.

 

1.20         “IND”
means an Investigational New Drug Application and any amendments thereto submitted to the FDA or any foreign counterparts or equivalents.

 

1.21         “Joint
Inventions” means patents, patent applications, inventions, improvements, discoveries, new uses, trade secrets, know-how,
results, reports, clinical development plans, Developments, drug master files, protocols, manufacturing, technical and any and
all other proprietary information and intellectual property, including but not limited to Chemistry, Manufacturing and Controls
(CMC) technical information, discovered or conceived by Licensee, whether solely or jointly with Advaxis or another party, as a
result of Licensee’s use of Licensed Technology.

 

    	5

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

1.22         
“Licensed Technology” means the technology disclosed in the Patent Rights and all know-how, trade secrets, and
proprietary information developed, owned or controlled, whether solely or jointly with another party (excluding Licensee), by Advaxis
or its Affiliates on the Effective Date or any time during the Term relating to the prevention and treatment of HPV-associated
diseases, the Product and ADXS-HPV.

 

1.23         
“Losses” means any and all damages (including all incidental, consequential, statutory and treble damages),
awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations,
taxes, liens, losses, lost profits and expenses (including court costs, interest and reasonable fees of attorneys, accountants
and other experts) required to be paid to Third Parties with respect to a claim as to which a Party is entitled to indemnification
under Article 14, by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into in accordance
with the provisions of this Agreement, together with all documented out-of-pocket costs and expenses incurred in complying with
any judgments, orders, decrees, stipulations and injunctions that arise from or relate to a claim of a Third Party.

 

1.24         
“Net Sales” means the gross amount invoiced by Licensee, its Affiliates or sublicensees to Buyers for sale of
Products, less, to the extent deducted by Licensee, its Affiliates or sublicensees from such gross invoice amount the following
amounts, all in accordance with GAAP:

 

(a)          trade
or cash discounts for prompt payment to the extent actually allowed;

 

(b)          promotional
allowances to the extent actually allowed;

 

(c)          price
adjustments to the extent actually allowed;

 

(d)          amounts
accrued or actually paid for chargebacks;

 

(e)          amounts
accrued or actually paid for rebates, including any and all non-government and government rebates;

 

(f)          amounts
accrued or actually refunded due to rejected, spoiled, damaged, outdated, short dated, or returned Product;

 

(g)          sales
and other excise taxes and duties or similar governmental charges levied on such sale, to the extent such items are included in
the gross amount invoiced; and

 

(h)          freight,
shipment and transportation costs incurred in distributing Products to a Buyer to the extent such amounts are included in the gross
amount invoiced;

 

If any Products are sold to Buyers in transactions
that are not at arm’s length between the buyer and seller, or for consideration other than cash, then the gross amount to
be included in the calculation of Net Sales for such sales shall be the amount that would have been invoiced had the transaction
been conducted at arm’s length, which amount shall be determined, whenever possible, by reference to the average selling
price of the relevant Product in arm’s-length transactions in the country of sale at the time of sale. Net Sales shall not
under any circumstance include any grant or amount received by Licensee from any Sponsor in connection with Licensee’s supply
of Products to such Sponsor for the purpose of conducting clinical trials. “Buyer” means a person or entity other than
Licensee, its Affiliates and sublicensees.

 

    	6

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

1.25         “New
Product” means any pharmaceutical product that is claimed or covered by any of the Licensed Technology or the Patent
Rights or both and is not used for the prevention or treatment of HPV-associated diseases.

 

1.26         “Party”
means Advaxis or Licensee, and “Parties” means Advaxis and Licensee.

 

1.27         “Patent
Rights” means the patents and patent applications set forth on Schedule 1.27 as well as any patents and patent applications
Covering the ADXS-HPV owned or controlled by Advaxis or its Affiliates during the Term, issued patents resulting from such applications,
and all divisions, continuations, substitutions, reissues, extensions, registrations, patent term extensions and renewals of the
foregoing.

 

1.28         “Person”
means any individual, firm, partnership, joint venture, association, corporation, limited liability company, trust, or other business
organization, entity or enterprise.

 

1.29         “Product”
means a pharmaceutical product that (i) includes ADXS-HPV as the active ingredient or (ii) uses or embodies Licensed Technology,
in each case for use within the Field.

 

1.30         
“Regulatory Approval” means any approvals (including pricing and reimbursement approvals), licenses, registrations
or authorizations of any national or international or local regulatory authority, department, bureau or other governmental entity,
necessary for the manufacture, marketing, distribution and sale of a Product in a regulatory jurisdiction for use in the Field
in the Territory.

 

1.31         “Sale
of the Field Business” means, with respect to either Party, any sale, divestment or other transfer of all or substantially
all of the Party’s then existing assets or business relating to HPV-related products, whether by asset sale, de-merger, spin-out,
public offering, reorganization or otherwise, and whether such sale, divestment or other transfer is to a Third Party.

 

1.32         “Sponsor”
means any governmental agency, medical institution, physician or other Person acting as a sponsor of a clinical trial.

 

1.33         “Term”
means the term of this Agreement, as more fully described in Section 16.1.

 

1.34         “Territory”
means the countries and territories listed on Schedule 1.34.

 

1.35         “Third
Party” means a person or entity other than (i) Advaxis or any of its Affiliates or (ii) Licensee or any of its Affiliates.

 

1.36         “U.S.
Prime Rate” means the base interest rate on corporate loans as published in the Wall Street Journal.

 

    	7

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

1.37         “Valid
Claim” means a claim in a Patent Right that Covers a Product and with respect to which none of the following ((i), (ii)
or (iii)) apply: (i) has been held permanently revoked, unenforceable or invalid in the Territory by a final unappealable decision
of a court or government agency of competent jurisdiction over such claim, (ii) has been admitted to be invalid or unenforceable
through disclaimers, consent decrees or otherwise or (iii) in the case of a patent application, has been pending for more than
seven (7) years after the filing of its first priority application.

 

ARTICLE
2

LICENSE GRANTS AND TECHNOLOGY TRANSFER

 

2.1           License
Grants. Subject to the terms and conditions of this Agreement, Advaxis hereby grants to Licensee an exclusive (even as to Advaxis
and its Affiliates) royalty-bearing license, with the right to grant sublicenses, under the Patent Rights and rights to Licensed
Technology to Develop, manufacture, have manufactured, import, use and Commercialize Products in the Field in the Territory.

 

2.2           Sublicense
Rights. At least twenty (20) days prior to sublicensing, Licensee shall provide a written notice to Advaxis. If Licensee grants
such a sublicense permitted hereunder, Licensee shall cause all of the applicable terms and conditions of this Agreement to apply
to the Affiliate or Third Party sublicensee. A copy of such sublicense agreement shall be made available to Advaxis upon request.

 

2.3           Non-Assert.
Advaxis and its Affiliates shall not assert any patents against Licensee’s, Licensee’s Affiliates’ and sublicensees’
Development, manufacture, having manufactured, importation, use and Commercialization of Products for use in the Field in the Territory.
For avoidance of doubt, Advaxis and its Affiliates shall also not assert any such patents against suppliers and customers of Licensee,
its Affiliates and its sublicensees, and any Third Party retained by Licensee in the performance of activities that this Agreement
permits Licensee to conduct; provided that such persons or entities Develop, manufacture, have manufactured, import, use and Commercialize
the Products for use in the Field in the Territory.

 

2.4           No
Implied Licenses. Except as expressly provided in this Agreement, neither Party grants to the other Party any right or license
in any intellectual property right, whether by implication, estoppel or otherwise. No implied licenses are granted under this Agreement.
Licensee hereby covenants and agrees not to use, sublicense, disclose or otherwise exploit any of the Licensed Technology
except as expressly permitted by this Agreement.

 

2.5           First
Right of Refusal for New Products. Advaxis and its Affiliates may Develop New Products during the Term that they are interested
in seeking to license for use in the Field in the Territory. In such event, prior to offering a license to a Third Party, Advaxis
shall promptly notify Licensee of any such New Product, together with a summary of relevant information to obtain such license
from Advaxis or its Affiliate on commercially reasonable terms. Upon Licensee’s receipt of such notice, the Parties shall
promptly commence and diligently undertake good faith negotiations for a period of thirty (30) days, in an effort to reach mutually
acceptable terms for such rights and license. During such thirty-day period, the New Product shall not be offered to any Third
Party. If the Parties are unable to reach a definitive agreement during such period, Advaxis may offer the New Product to a Third
Party. In the event that any Third Party offers terms acceptable to Advaxis or its Affiliate for licensing, Advaxis shall provide
written notice to Licensee of such terms and offer Licensee the right to license under the same terms; such offer to license shall
lapse after thirty (30) days from the date of written notice. Advaxis or its Affiliate shall not enter into any licensing agreement
until after such offer to Licensee lapses.

 

    	8

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

2.6           Technology
Transfer and Support 

 

(a)          
Upon Licensee’s request from time to time, Advaxis shall promptly deliver, at Advaxis’s cost and expense, to Licensee
any reasonably available documentation, records and other tangible items that are necessary to enable Licensee to manufacture,
have manufactured, use and Commercialize Products (“Deliverables”) in accordance with the terms of this
Agreement. Deliverables include recombinant Listeria monocytogenes (“Lm”) strains, plasmids, master cell
bank, cell lines, and commercially unavailable reagents.

 

(b)          Upon
Licensee’s request from time to time, Advaxis shall provide, at Advaxis’s cost and expense, training to Licensee
personnel and a reasonable amount of support with respect to the Licensed Technology, including answering questions and providing
verbal advice, to enable Licensee to manufacture, have manufactured, use and Commercialize Products.

 

ARTICLE
3

GOVERNANCE

 

3.1           Joint
Steering Committee.

 

(a)          Establishment
and Composition. The Parties shall establish a joint steering committee (the “Joint Steering Committee”)
and this co-committee shall be co-chaired by a representative of each of Advaxis and Licensee.

 

(b)          Purpose.
The purpose of the Joint Steering Committee is to provide a forum for the exchange of information between the Parties so as to
enable the Parties to fulfill their obligations under this Agreement and enhance the commercial success of the Product.

 

(c)          Responsibilities.
The Joint Steering Committee shall have the following responsibilities and perform the following functions relating to Products
pursuant to this Agreement:

 

(i)          Discuss,
facilitate and coordinate the exchange of information between the Parties;

 

(ii)         Discuss
and review: (A) Product Development strategies, (B) prioritization of the Development of Products, and (C) the preparation and
implementation of the Development plans;

 

    	9

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(iii)        Discuss
and review: (A) Product Commercialization strategies, and (B) the preparation and implementation of the Commercialization plans
for the Products;

 

(iv)        Discuss
and review regulatory strategies and submissions, Product labeling strategies and related activities;

 

(v)         Discuss
and review Product supply strategies; and

 

(vi)        Have
such other responsibilities as may be mutually agreed in writing by the Parties from time to time.

 

(d)          Meetings.
The Joint Steering Committee shall meet at least four times during every Calendar Year of which at least two times during every
Calendar Year shall be in person, and more frequently as the Parties deem appropriate, on such dates, and at such places and times,
as the Parties shall agree. Meetings of the Joint Steering Committee that are held in person shall be at a place as such Parties
may agree.

 

(e)          Decision-Making.
Licensee shall have final decision-making authority on all matters coming before the Joint Steering Committee pertaining to the
Products in the Territory.

 

3.2           Minutes
of Committee Meetings. Definitive minutes of the Joint Steering Committee meetings shall be finalized no later than ten (10)
business days after the meeting.

 

3.3           Expenses.
Each Party shall be responsible for all travel and related costs and expenses for its members and other representatives to attend
meetings of, and otherwise participate on, the Joint Steering Committee.

 

ARTICLE
4

DEVELOPMENT

 

4.1           Product
Development. Advaxis and Licensee shall be responsible for and shall use Commercially Reasonable Efforts in conducting all
Development for the Product; provided that Licensee shall be responsible for seeking Regulatory Approval of Products in
the Territory and for maintaining Regulatory Approval of the Product in the Territory. Licensee agrees at its cost to provide up
to 1/3 of the patients, but not more than 150 patients, needed for Advaxis’s U.S. registrational study. Licensee may also
use in Licensee’s own clinical trials the data derived from all of the patients in Advaxis’s U.S. registrational study.

 

4.2           Development
Reports. With respect to each Product, each Party shall provide to the other Party, no less than annually, a development update
report relating to such Product for such Party’s use to assess the status of the Development of each Product.

 

4.3           Development
Data. Each Party shall provide to the other Party copies of all substantive or material information with respect to Development
hereunder, including, as applicable, final laboratory and clinical data and reports compiled with respect to each Product as soon
as reasonably practicable after such data or report becomes available. The relevant Party shall own all clinical data and results
related to all of the Products it generates through its Development activities, provided that the other Party will have access
thereto on a royalty-free basis for use in its exercise of its retained rights.

 

    	10

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

4.4           Use
of Third Parties. Each Party may retain Third Parties to perform Development activities hereunder. Advaxis and Licensee shall
remain liable for the performance of their respective obligations hereunder which they delegate to such Third Parties. Any Third
Party performing Development hereunder shall be subject to confidentiality and non-use obligations at least as stringent as those
set forth in Article 12 and must comply with Article 11.

 

4.5           Diligence.
From and after the Effective Date, Licensee shall use Commercially Reasonable Efforts to Develop the Products for Commercialization
in the Territory.

 

ARTICLE
5

REGULATORY AFFAIRS

 

5.1           Regulatory
Submissions and Approvals. Licensee, at its sole cost, shall pursue all Regulatory Approvals related to the Products in the
Territory, including the preparation and filing of applications for clinical trials and Regulatory Approvals. Licensee shall own
and maintain, at its sole cost, all regulatory filings and Regulatory Approvals for the Products in the Territory. Licensee shall
promptly provide Advaxis with complete copies of all such applications, submissions, filings and regulatory correspondence related
to the Products in the Territory. In the event that Licensee wishes to discontinue the pursuit or maintenance of a Regulatory Approval
in any part of the Territory, Advaxis shall have the right to step in and assume the pursuit or maintenance of such Regulatory
Approvals at its sole cost and Licensee shall transfer ownership of such Regulatory Approval and all documents related thereto
to Advaxis, provided that Advaxis shall reimburse Licensee for all reasonable costs and expenses incurred by Licensee to pursue
or maintain the Regulatory Approval.

 

5.2           Pharmacovigillance.

 

(a)          The
Parties agree to inform each other about serious adverse events occurring or having occurred in connection with the Development
or Commercialization of Products anywhere in the world within five (5) business days of when the Party who is the sponsor of the
relevant study first learns of such event. The Parties agree to handle data and information about such serious adverse events according
to all applicable laws, rules and regulations. To the extent of any Development or Commercialization of the same Products inside
and outside of the Territory, the Parties shall enter into a worldwide safety information exchange and reporting agreement to coordinate
such matters between the Parties.

 

(b)          The
Joint Steering Committee shall specify the procedure for exchange of information relating to serious adverse events.

 

    	11

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

5.3           Data
Access. 

 

(a)          Licensee
shall permit Advaxis access to, and grant Advaxis the right to reference and use, all Development and regulatory data and reports
associated with any Product in the Territory at no cost for use (1) outside the Territory with respect to any product of Advaxis
or its Affiliates or sublicensees or designees and (2) inside the Territory only with respect to non-HPV-related products of Advaxis
or its Affiliates or sublicensees or designees. In furtherance of the foregoing, Licensee shall, promptly upon the request of Advaxis,
deliver a letter to the FDA (or the relevant regulatory authority) authorizing Advaxis to reference and use the applicable regulatory
submissions and filings related to Products in the Territory (1) outside the Territory with respect to any product of Advaxis or
its Affiliates and (2) inside the Territory only with respect to non-HPV-related products of Advaxis or its Affiliates.

 

(b)          Advaxis
shall permit Licensee access to, and grant Licensee the right to reference and use, all Development and regulatory data and reports
associated with any Product at no cost with respect to any Product of Licensee or its Affiliates or sublicensees or designees.
In furtherance of the foregoing, Advaxis shall, promptly upon the request of Licensee, deliver a letter to the relevant regulatory
authority in the Territory authorizing Licensee to reference and use the applicable regulatory submissions and filings related
to the Products. Upon Licensee’s request, Advaxis shall also assist Licensee with obtaining consent from Advaxis’s
other licensees for Licensee to use such other licensees’ Development and regulatory data and reports associated with any
Products at no cost, including consent to deliver a letter to the relevant regulatory authority in the Territory authorizing Licensee
to reference and use the applicable regulatory submissions and filings related to the Products.

 

ARTICLE
6

COMMERCIALIZATION

 

6.1           Overview
and Diligence. Licensee shall be responsible for Commercializing the Products in the Territory and all costs and expenses in
connection therewith.

 

6.2           Expenses
and Responsibilities. Consistent with the license rights granted to Licensee under Article 2, Licensee, its Affiliates and
its sublicensees shall (a) have the sole right and responsibility to distribute, sell, record sales and collect payments for Products
in the Territory, and (b) have sole right and responsibility for establishing and modifying the terms and conditions with respect
to the sale of Products in the Territory, including the price or prices at which Products in the Territory will be sold, any discount
applicable to payments or receivables, and similar matters.

 

6.3           Diligence.
Licensee shall use Commercially Reasonable Efforts to Commercialize the Products in the Territory. Licensee agrees that during
the Term, other immunotherapies in the Field in the Territory to be commercialized by Licensee shall be intended to complement
the Products and would not be reasonably expected to negatively impact commercialization of the Products.

 

    	12

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

ARTICLE
7

PRODUCT SUPPLY

 

7.1           Supply
of the Product.

 

(a)          For
each Product, Advaxis, in consultation with Licensee, shall be responsible for manufacturing, packaging, labeling, release testing,
and stability testing for laboratory and clinical supplies required for obtaining Regulatory Approval in the Territory for such
Product.

 

(b)          Upon
Licensee’s request, Advaxis shall propose a budget stating the best estimate of the funds required for manufacturing, packaging,
labeling, release testing, and stability testing for laboratory and clinical supplies. Licensee shall pay for all of Advaxis’s
costs for raw materials, manufacturing, packaging, labeling, release testing, and stability testing and any other costs associated
with clinical and commercial supplies of the Product on an “as incurred” basis, without any mark-up, provided that
these costs do not exceed any applicable budget proposed by Advaxis for which Advaxis has obtained Licensee’s prior approval.

 

7.2           Transition
to Licensee. As soon as it is reasonably practicable, Advaxis will transition to Licensee the manufacturing, packaging, labeling,
release testing, and stability testing for laboratory and clinical supplies required for obtaining Regulatory Approval in the Territory
and, thereafter, Licensee shall be responsible, at its sole cost and expense, for sourcing raw materials, manufacturing, packaging,
labeling, release testing, and stability testing the clinical and commercial supplies of the Products in the Territory. The Parties
shall further cooperate and undertake the actions necessary to qualify Licensee as a secondary supplier of the Product. Licensee
and any manufacturer of commercial supplies of any Product on Licensee’s behalf shall also make such Product available to
Advaxis on a “cost plus” basis to be negotiated among the Parties. In addition, Advaxis will give Licensee an opportunity
to bid on all of Advaxis’s Product manufacturing needs following the expiration of Advaxis’s planned agreement with
Synco.

 

ARTICLE
8

PAYMENTS

 

8.1           Upfront
Payment and Share Purchase. On the Effective Date, Licensee shall make a payment to Advaxis of four hundred thousand dollars
($400,000), which payment shall be non-refundable and non-creditable, in immediately available funds to an account designated by
Advaxis and Advaxis shall issue and deliver to Licensee, or its nominee, shares of common stock of Advaxis (the “Shares”).
The number of Shares to be delivered to Licensee shall be calculated based upon a share price equal to the volume weighted average
closing price of Advaxis’s common stock as of the last ten (10) trading days immediately prior to the Effective Date (“Share
Price for the $400,000 Payment”). In addition, Advaxis shall issue and deliver a warrant to Licensee which will entitle
Licensee to purchase from time to time up to an aggregate of one hundred thousand (100,000) Shares. The warrant shall have a per
share exercise price equal to 150% of the Share Price for the $400,000 Payment, and shall expire five (5) years from Effective
Date. Licensee agrees that it will not sell, pledge, hypothecate or otherwise transfer the economic risk of ownership of the Purchased
Shares except to an Affiliate of the Licensee that agrees to be bound by the restrictions on transfer contained in this Section
8.1 until the second anniversary of the Effective Date. In addition, the Parties understand that the Purchased Shares will be “restricted
securities” for purposes of the United States securities laws and will bear a restrictive legend stating that the Shares
have not been registered under the United States Securities Act of 1933, as amended, and may not be transferred or sold except
as permitted thereunder pursuant to registration or an exemption from registration. “Purchased Shares”
shall mean the Shares to be purchased by the Licensee on the Effective Date pursuant to this Section 8.1 from Advaxis.

 

    	13

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

8.2           Annual
Exclusive License Fee. On each anniversary following the first anniversary of the Effective Date during the Term, Licensee
shall make a payment to Advaxis of [c.i.] (each such payment, an “Exclusive
License Fee”). For the avoidance of doubt, the first such payment shall be due on December 15, 2015. Licensee’s
obligation to pay Exclusive License Fee hereunder shall expire on the year that Licensee commences payment of royalty under Section
9.2. Further, any and all such Exclusive License Fees paid hereunder shall be creditable against any Royalty Payments required
to be made pursuant to Article 9 until such time as all Exclusive License Fees previously paid have been fully credited against
such Royalty Payments. Licensee shall not be obligated to pay any additional fees and shall not be additionally charged on the
ground that the Exclusive License Fee does not cover any Licensed Technology developed, owned or controlled, whether solely or
jointly with another party, by Advaxis and its Affiliates prior to the Effective Date.

 

8.3           Milestone
Payments. Unless otherwise provided in Schedule 8.3, within ten (10) business days of achieving each milestone event set forth
in Schedule 8.3, Licensee shall pay Advaxis the milestone payments related to such milestone event in the amounts set forth on
Schedule 8.3.

 

8.4           Development
Expenses. Each Party shall bear its own expenses under this Agreement, except that Licensee shall pay Advaxis Development Expenses
for which Advaxis has obtained prior written approval from Licensee pursuant to Section 8.5.

 

8.5           Requirements
for Licensee Reimbursement of Advaxis Development Expenses.  Licensee shall pay Advaxis only for Advaxis Development
Expenses for which Advaxis has obtained prior written approval from Licensee, which approval may not be unreasonably withheld.
Advaxis shall propose a budget constituting the best estimate of the funds required to timely complete the proposed Development
activities. In no event shall Advaxis charge Licensee any amounts incurred in excess of the cap on the total budget as set forth
in a budget that has been approved by Licensee, nor shall Licensee be liable to pay such amounts; provided further that in no event
shall Advaxis be required to perform Development activities which would not be eligible for reimbursement.

 

8.6           Invoices.
Within ten (10) business days after the end of each month, Advaxis shall provide Licensee with a good faith estimate for all Advaxis
Development Expenses incurred by Advaxis for such month. In addition, within thirty (30) days after the end of each Calendar Quarter,
Advaxis shall provide Licensee with an invoice for all Advaxis Development Expenses incurred by Advaxis for such Calendar Quarter
which invoice shall set forth the details of the charges for each activity together with appropriate documentation. Advaxis shall
also provide a report stating the progress and results from the activities associated with the Advaxis Development Expenses. Within
thirty (30) days after the date of each such invoice received, Licensee shall pay in full such invoice. If any portion of an invoice
is disputed, then Licensee shall pay the undisputed amounts as set forth in the preceding sentence and the Parties shall use good
faith efforts to reconcile the disputed amount as soon as practicable. Notwithstanding the previous sentence, if Licensee disputes
a charge or charges on an invoice, Licensee will pay the amount ultimately determined to be due, if any, within thirty (30) days
after Licensee and Advaxis, acting in good faith, resolve the dispute.

 

    	14

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

ARTICLE
9

ROYALTIES

 

9.1           Royalty
Payments. (a) Licensee shall pay Advaxis a royalty based upon the following tiered structure with respect to any sale of a
Product in the Territory: Net Sales of such Products in such Territory up to and including $50 million at [c.i.] of Net Sales,
Net Sales of such Products in such Territory greater than $50 million and up to and including $100 million at [c.i.] of Net Sales
and Net Sales of such Products in such Territory above $100 million at [c.i.] of Net Sales. For example, if Net Sales of such Product
is $101 million, then the royalty rate applicable on such Net Sales shall be calculated as follows:

 

[c.i.]

 

Notwithstanding the foregoing, if Advaxis
does not own any pending patent applications as of the Effective Date and listed on Schedule 1.27 or issued patents that Cover
Products in a country within the Territory, the royalty shall be based on [c.i.] of Net Sales of Products sold in such country.

 

(b)          Cross-Royalty.
In consideration of the Development expenses to be incurred by Licensee in the Territory, Advaxis shall pay Licensee a cross-royalty
of [c.i.] of Advaxis’s U.S. Sales of Products during the Royalty Term.

 

9.2           Term
of Royalty Payments. Licensee’s obligation to make royalty payments to Advaxis under Section 9.1 shall commence upon
the First Commercial Sale of the first Product in any country in the Territory (the “Royalty Commencement Date”)
and shall expire (the “Royalty Term”) upon the later of (i) expiration of the last to expire Valid Claim
Covering a Product in the issued patents and pending patent applications listed in Schedule 1.27 and (ii) twenty (20) years from
the Effective Date. Thereafter, the licenses shall be fully paid up, royalty-free and irrevocable.

 

9.3           Timing
of Royalty Payments and Reports by Licensee. Beginning with the first Calendar Quarter in which the Royalty Commencement Date
occurs, Licensee shall make royalty payments to Advaxis within one hundred twenty (120) days after the end of each Calendar Quarter
based on Net Sales of Products sold during each such Calendar Quarter. Beginning with the month of the First Commercial Sale, within
five (5) business days after the end of each month, Licensee shall provide to Advaxis a good faith estimate of Net Sales for such
month.

 

    	15

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

9.4           Timing
of Cross-Royalty Payments and Reports by Advaxis. Beginning with the first Calendar Quarter in which the Royalty Commencement
Date occurs, Advaxis shall make cross-royalty payments to Licensee within one-hundred twenty (120) days after the end of each Calendar
Quarter based on Advaxis’s U.S. Sales of Products during each such Calendar Quarter. Beginning with the month of First Commercial
Sale, within five (5) business days after the end of each month, Advaxis shall provide to Licensee a good faith estimate of Advaxis’s
U.S. Sales of Products for such month.

 

9.5           Payment
of Net Amount. The Parties agree that at least ten (10) days prior to the date that royalty and cross-royalty payments are
due pursuant to Sections 9.3 and 9.4, Advaxis and Licensee shall calculate the net amount payable by one Party to the other Party
pursuant to Sections 9.3 and 9.4 after giving effect to any credits pursuant to Section 8.2 and the Party that owes such amount
to the other Party shall make such payment within the time frames specified by Section 9.3 or 9.4, as applicable.  

 

ARTICLE
10

ACCOUNTING AND AUDITING

 

10.1        Currency.
All payments under this Agreement are stated in and shall be payable in US dollars by wire transfer to a bank in the United States
designated in writing by Advaxis or Licensee, as the case may be.

 

10.2        Payments.

 

(a)          With
each payment to Advaxis under this Agreement, Licensee shall deliver to Advaxis the following information, including payment methodology
calculations:

 

(i)          Net
Sales for each Product, details and methodology of the gross sales to Net Sales calculation, and methodology and calculation for
the royalty payments; and

 

(ii)         Details
relating to any milestone payments to Advaxis.

 

(b)          Subject
to Sections 8.6 and 10.4, in case of any delay in payment by a Party to the other Party, interest on the overdue payment shall
accrue at an annual interest rate, compounded monthly, equal to the U.S. Prime Rate as reported in The Wall Street Journal, plus
one and a half percentage points (1.5%), as determined for each month on the last business day of that month, assessed from the
day payment was initially due. The foregoing interest shall be due from such delinquent Party without any special notice. In the
event of any overpayment by Licensee, the amount of such overpayment shall be credited against the next payment due from Licensee
to Advaxis under this Agreement.

 

(c)          Currency
Conversion. Whenever, for the purpose of calculating any sums due under this Agreement, conversion from any foreign currency
shall be required, such conversion shall be made as follows: (i) when calculating the Net Sales, the amount of such sales in foreign
currencies shall be converted into United States dollars using the average rate of exchange for such currencies for the relevant
period, and (ii) when calculating Development expenses that are incurred in a currency other than in United States dollars, the
amount in foreign currencies shall be converted into United States dollars using the exchange rates for such currencies for the
average monthly rate of the respective invoice. In respect of (i) and (ii) above, such exchange rate shall be the mid-price exchange
rate taken from The Wall Street Journal as published on the date of the relevant invoice or such other publication as may be agreed
between the Parties from time to time.

 

    	16

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

10.3        Taxes.
Advaxis shall be responsible for all income, withholding and other taxes levied on Advaxis or its Affiliates under the laws or
regulations of any country in the Territory. If Licensee makes withholding payments as may be required for and on behalf of Advaxis
or its Affiliates to the proper governmental authority, Licensee may subtract such withholding payments from the royalties due
hereunder. Licensee shall submit appropriate proof of payment of such withholding taxes to Advaxis within a reasonable period of
time.

 

10.4        Accounting.

 

(a)          During
the Term and for a period of three (3) years thereafter, each Party shall, and shall cause its Affiliates and sublicensees to,
maintain at its respective principal places of business, records and books of account containing all particulars that may be necessary
for the purpose of calculating all payments due under this Agreement. During the Term and for a period of three (3) years thereafter,
but no more than once during any Calendar Year, each Party shall have the right to engage an independent, certified public accountant(s),
reasonably acceptable to the other Party, to perform, on behalf of such Party, an audit of the other Party’s books and records
and those of its Affiliates and sublicensees as may be necessary to confirm any amounts payable to the auditing Party under this
Agreement for the period or periods requested by the auditing Party or to confirm the accuracy of any report made under this Agreement.

 

(b)          Such
audits shall be conducted during normal business hours upon reasonable prior written notice from the auditing Party in such a manner
as to not unnecessarily interfere with the audited Party’s or its Affiliate’s or sublicensees normal business activities,
and shall be permitted with respect to records and books covering and including the three (3) years immediately preceding the date
of notification of the audit. The accountants shall report its conclusions and calculation to both Parties; provided, however;
that in no event shall the accountants disclose information of the audited party except to the extent necessary to verify the accuracy
of the payments due under this Agreement, and at the request of the audited party such accountants shall execute appropriate non-disclosure
agreements.

 

(c)          The
auditing Party shall use all information, data, documents and abstracts obtained during an audit conducted pursuant to this Section
10.4 solely for the purposes described in Section 10.4(a). The auditing Party shall treat all such information, data, documents
and abstracts as the audited Party’s Confidential Information subject to Article 12 of this Agreement and, except in the
event of a dispute between the Parties regarding amounts payable hereunder or the results of any audit, the auditing Party shall
not retain such information, data, documents and abstracts for more than three (3) years from the end of the Calendar Year to which
each shall pertain.

 

(d)          If
any audit hereunder reveals an underpayment, the Party responsible for the underpayment shall promptly make up such underpayment.
If any audit hereunder reveals an overpayment, the Party holding the overpayment shall promptly reimburse such overpayment. The
auditing Party shall bear the full cost of any audit under this Section 10.4, unless such audit discloses an underpayment by the
audited Party of more than five percent (5%) of the amount owed hereunder in which case the audited Party shall bear the full cost
of such audit.

 

    	17

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(e)          The
failure of an auditing Party to request verification of any payment calculation within the three (3) year period following receipt
of such payment shall be considered acceptance of such calculation by the auditing Party.

 

ARTICLE
11

INTELLECTUAL PROPERTY

 

11.1        Ownership
of Inventions.

 

(a)          Joint
Inventions. Advaxis and Licensee shall jointly own all Joint Inventions. Upon Advaxis’s receipt of written disclosure
from Licensee under subsection (b) hereunder, the Parties shall promptly commence and diligently undertake good faith negotiations
in an effort to reach mutually acceptable terms on the Parties’ relative rights in relation to the Joint Invention and to
compensate for Licensee’s contribution.

 

(b)          Inventor
ship. Licensee agrees promptly to provide to Advaxis a complete written disclosure of any Joint Inventions.

 

11.2        Prosecution
and Maintenance of Patent Rights.

 

(a)          Patent
Rights. Advaxis shall be solely responsible for the filing, prosecution and maintenance of the Patent Rights; provided, however:

 

(i)          Advaxis
shall not allow any Patent Rights in the Territory to lapse or become abandoned and/or to disclaim or concede priority with respect
to any invention disclosed or claimed in the Patent Rights in the Territory claiming a Product (an “Abandoned Patent”)
without first providing Licensee a written notice thereof. If Licensee so requests, Advaxis will continue to maintain and prosecute
the Abandoned Patents in the Territory; provided, that the costs and expenses of maintaining and prosecuting the Abandoned Patent
shall be first paid by Licensee and Licensee may deduct such costs and expenses from any Exclusive License Fee due and payable
to Advaxis.

 

(ii)         Advaxis
shall promptly provide copies to Licensee of any filings made to, and any material written communications received from, any patent
office in the Territory relating, in whole or in part, to any Patent Rights in the Territory. Advaxis shall give reasonable consideration
to any comments that may be made by Licensee relating to the prosecution or maintenance of the Patent Rights in the Territory.

 

(iii)        Except
as expressly agreed otherwise, Advaxis shall be responsible for its costs and expenses in preparing, filing, prosecuting and/or
maintaining the Patent Rights Covering Products in the Territory.

 

    	18

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(b)          Other
Patent Rights.

 

(i)          Advaxis
shall have full responsibility for, and shall control the preparation and prosecution of, all patent applications and the maintenance
of all patents relating to Licensed Technology in and outside the Territory.

 

(ii)         Advaxis
shall determine whether any Licensed Technology is patentable, and if so, shall proceed, at its discretion, with the preparation
and prosecution of a patent application covering any such Licensed Technology. Notwithstanding the foregoing, Licensee may request
that Advaxis file, prosecute and maintain patent applications with respect to Licensed Technology inside the Territory, where Advaxis
has elected not to file, prosecute or maintain a patent application; provided, that the costs and expenses of filing, prosecuting
and maintaining such patent applications and patents in such jurisdictions shall be first paid by Licensee and Licensee may deduct
such costs and expenses from any Exclusive License Fee due and payable to Advaxis.

 

(c)          Cooperation.
Licensee agrees to cooperate with Advaxis with respect to the preparation, filing, prosecution and maintenance of the Patent Rights.

 

11.3        Third
Party Infringement.

 

(a)          Notice.
Each Party shall promptly report in writing to the other Party during the Term any known (i) infringement of any of the Patent
Rights in the Territory or (ii) unauthorized use of any of the Licensed Technology in the Territory of which such Party becomes
aware, including, in the case of either clause (i) or clause (ii) involving the Development, manufacture or Commercialization by
a Third Party of a competing product in the Territory (a “Competitive Infringement”) and Licensee shall provide
Advaxis with all available evidence supporting such known infringement or unauthorized use.

 

(b)          Initial
Right to Enforce. Subject to Section 11.3(c), Advaxis shall have the first right (but not the obligation) to initiate a suit
or take other appropriate action that it believes is reasonably required to protect (i.e., prevent or abate actual or threatened
infringement or misappropriation of) or otherwise enforce the Patent Rights and Licensed Technology in the Territory. In the event
that Advaxis does not pursue an enforcement action within a period of one hundred eighty (180) days following reasonable notification
of the Competitive Infringement, then Licensee shall have the right to bring such action at its own expense.

 

(c)          Conduct
of Certain Actions; Costs. The Party initiating suit shall have the sole and exclusive right to select its counsel for any
suit initiated by it pursuant to Section 11.3(b) and shall have the sole exclusive control regarding the suit and settlement; provided
that neither Party shall settle or compromise any Competitive Infringement without the consent of the other Party, which consent
shall not be unreasonably withheld. If required under applicable law in order for the initiating Party to initiate and/or maintain
such suit, the other Party shall join as a party to the suit. Such other Party shall offer reasonable assistance to the initiating
Party in connection therewith at no charge to the initiating Party except for reimbursement of reasonable out-of-pocket expenses
incurred in rendering such assistance. The initiating Party shall assume and pay all of its own out-of-pocket costs incurred in
connection with any litigation or proceedings initiated by it pursuant to Section 11.3(b), including the fees and expenses of the
counsel selected by it. The other Party shall have the right to participate and be represented in any such suit that is based on
a Competitive Infringement by its own counsel at its own expense.

 

    	19

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(d)          Recoveries.
With respect to any suit or action referred to in Section 11.3(b), any recovery obtained as a result of any such proceeding, by
settlement or otherwise, shall be paid to the Party that initiated such suit or action.

 

11.4        Patent
Invalidity Claim. If a Third Party at any time asserts a claim that any Patent Rights are invalid or otherwise unenforceable
(an “Invalidity Claim”), Advaxis shall control the response to such Invalidity Claim in the Territory. Neither
Party shall settle or compromise any Invalidity Claim without the consent of the other Party, which consent shall not be unreasonably
withheld. If an Invalidity Claim arises in connection with a suit or action referred to in Section 11.3(b), the Parties shall
confer with one another regarding the appropriateness of having the Party that is controlling such suit or action in accordance
with Section 11.3(b) continue to control such suit or action and the sharing of cost and expenses with respect to such suit or
action; provided that in the absence of any agreement by the Parties to the contrary, control of the Invalidity Claim shall remain
with the same Party, and the costs and expenses of responding to the Invalidity Claim shall be borne by the Parties in accordance
with Section 11.3(d). If the Invalidity Claim does not arise in connection with a suit or action referred to in Section 11.3(b),
the costs and expenses of responding to the Invalidity Claim shall be borne by the Party that controlled such response.

 

11.5        Claimed
Infringement. In the event that a Party becomes aware of any Claim that the practice by Licensee of Licensed Technology in
the Development, manufacture or Commercialization of a Product in the Territory infringes the intellectual property rights of any
Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall cooperate with one another.
Each Party shall provide to the other Party copies of any notices it receives from Third Parties regarding any patent nullity actions,
any declaratory judgment actions and any alleged infringement or misappropriation of Third Party intellectual property relating
to the Development, manufacture or Commercialization of a Product. Such notices shall be provided promptly, but in no event after
more than ten (10) days following receipt thereof. Notwithstanding anything else to contrary under this Agreement, and without
limiting any right or remedy Licensee may otherwise have under this Agreement or at law or in equity: (a) Licensee shall, after
consulting with Advaxis, have the right (but not the obligation) to enter into intellectual property license agreements with such
Third Parties as Licensee reasonably believes to be necessary to avoid or settle allegations or claims regarding freedom to operate
in the Territory (other than for trademarks or copyrights) against a Product (other than the extended release formulation characteristics
or technology of a Product) by such Third Party against either Party to this Agreement and (b) Licensee may deduct from and set
off against any royalties owed to Advaxis hereunder any royalties and other license payments paid under such license agreements
to such Third Parties.

 

    	20

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

11.6         Patent
Term Extensions. The Parties shall cooperate, if necessary and appropriate, with each other in gaining patent term extension
wherever applicable to Patent Rights in the Territory that Cover Products. The Parties shall, if necessary and appropriate, use
reasonable efforts to agree upon a joint strategy relating to patent term extensions, but, in the absence of mutual agreement with
respect to any extension issue in the Territory, if Advaxis does not wish to file for an extension of a Patent Right in the Territory
that Covers a Product, then Advaxis shall timely let Licensee know sufficiently in advance so as to permit Licensee to request
Advaxis to file for such extension, in which case, Advaxis shall file such extension at Licensee’s expense.

 

11.7         Patent
Marking. Licensee agrees to comply with the patent marking statutes in each country in the Territory in which Products are
sold by Licensee, its Affiliates and/or its sublicensees.

 

ARTICLE
12

CONFIDENTIAL INFORMATION

 

12.1         Treatment
of Confidential Information. In carrying out its obligations under this Agreement, each Party will be sharing confidential
and proprietary data and information (“Confidential Information”) with the other Party.  Except as expressly
permitted by this Agreement, each Party shall, and shall cause its Affiliates to, treat Confidential Information received from
the other Party (the “Disclosing Party”) or its Affiliates as it treats its own proprietary information of like
nature and importance. During the Term and for a period of five (5) years thereafter, the Party in receipt of the Disclosing Party’s
Confidential Information (the “Receiving Party”) shall not disclose, divulge or otherwise communicate such Confidential
Information to any Third Party, or use it for any purpose except pursuant to and in order to carry out its obligations under this
Agreement. Notwithstanding the foregoing, the Receiving Party may disclose Confidential Information of the Disclosing Party to
the Receiving Party’s directors, officers, employees, Affiliates, consultants, subcontractors, sublicensees or agents to
the extent reasonably necessary to carry out its obligations under this Agreement, provided that such directors, officers, employees,
Affiliates, consultants, subcontractors, sublicensees or agents have been advised of the confidential nature of such information
and have agreed to maintain such information as confidential to the same extent required by this Article 12.

 

12.2         Exceptions
to Definition of Confidential Information. Confidential Information shall not include information that the Receiving Party
can demonstrate:

 

(a)          was
known by the Receiving Party or its Affiliates prior to the date it was disclosed to the Receiving Party or its Affiliates by the
Disclosing Party or its Affiliates, as evidenced by the prior written records of the Receiving Party or its Affiliates;

 

(b)          is
lawfully disclosed to the Receiving Party or its Affiliates by a Third Party rightfully in possession of such information, either
before or after the date of the disclosure to the Receiving Party or its Affiliates;

 

(c)          becomes
generally known to the public through no act or omission on the part of the Receiving Party or its Affiliates, either before or
after the date of the disclosure to the Receiving Party or its Affiliates;

 

    	21

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(d)          is
independently developed by the Receiving Party or its Affiliates without reference to or reliance upon any Confidential Information
of the Disclosing Party or its Affiliates; or

 

(e)          is
required to be disclosed by the Receiving Party or its Affiliates pursuant to a judicial or governmental order, provided that the
Receiving Party gives the Disclosing Party sufficient notice to permit Disclosing Party to seek a protective order or other similar
order with respect to such Confidential Information.

 

12.3        Exceptions.
The restrictions set forth in this Article 12 shall not prevent either Party from (i) disclosing Confidential Information in connection
with preparing, filing, prosecuting or maintaining the Patent Rights Covering a Product in accordance with Article 11, (ii) disclosing
Confidential Information to governmental agencies to the extent required or desirable to obtain a Regulatory Approval, (iii) disclosing
Confidential Information to actual or potential private investors or lenders (under customary confidentiality obligations for such
third parties) in connection with fundraising activities, (iv) disclosing Confidential Information to underwriters and financial
advisors (under an obligation of confidentiality) in connection with the public offering of securities, or (v) disclosing Confidential
Information that is reasonably determined is required to be disclosed by the Receiving Party (to comply with applicable securities
or other laws) to public investors or governmental agencies in connection with the public offering of securities, provided that
in all of the above cases, the Party disclosing Confidential Information of the Disclosing Party shall use all reasonable efforts
to provide prior written notice of such disclosure to the Disclosing Party and to take reasonable and lawful actions to avoid or
limit such disclosure or to assist the Disclosing Party in avoiding or limiting such disclosure. Further, either Party may also
disclose the existence and terms of this Agreement to its attorneys and advisors, to potential acquirers in connection with a potential
Change of Control or Sale of the Field Business and to existing and potential investors or lenders of such Party, as a part of
their due diligence investigations, or to potential permitted assignees, in each case under an agreement to keep the terms of this
Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement.

 

12.4        Publications.
Subject to Section 12.5 and except as required pursuant to law or regulation, the following provisions shall apply to the Parties
with respect to all publications, presentations and other public disseminations of any information relating to Products or to Development,
manufacturing, or Commercialization performed pursuant to the Agreement:

 

(a)          The
Party desiring to publish, present or otherwise publicly disseminate such information (the “Publishing Party”)
shall provide the other Party with a copy of any proposed publication, presentation or other public dissemination at least forty-five
(45) days prior to submission for publication, presentation or other public dissemination so as to provide such other Party an
opportunity to recommend any changes it reasonably believes are necessary to preserve the Confidential Information belonging in
whole or in part to such other Party or to preserve such other Party’s ability to obtain a patent or patents Covering any
invention. The incorporation of such recommended changes shall not be unreasonably refused.

 

    	22

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

(b)          If
such other Party provides written notice (“Notice”) to the Publishing Party within thirty (30) days of receipt
of the copy of the proposed publication, presentation or other public dissemination that such publication, presentation or other
public dissemination in its reasonable judgment (i) discloses information about an invention for which the other Party desires
patent protection or (ii) discloses Confidential Information of the other Party, the Publishing Party shall prevent such publication
or delay such publication, presentation or other dissemination until the Parties have agreed on mutually acceptable modifications
thereto so as not to prejudice the other Party’s right to obtain a patent and not to disclose the other Party’s Confidential
Information. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and
filing of a patent application(s).

 

12.5         Publicity.
The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of the press
release attached as Schedule 12.5. Neither Party shall issue any other news release or make any other public announcement, written
or oral, relating to this Agreement, including its terms, or the Products with respect to the Territory, without the prior approval
of the other Party. Each Party shall limit public disclosure of the financial terms set forth in this Agreement to the minimum
extent required by law (by, for example, requesting confidential treatment of such terms in documents required to be filed with
the US Securities and Exchange Commission); provided, however, the Parties may, after any required public disclosure for compliance
with any applicable law, including securities laws, reference such financial terms in news releases or oral statements without
seeking approval from the other Party.

 

ARTICLE
13

REPRESENTATIONS AND WARRANTIES

 

13.1         Mutual
Representations and Warranties. Each Party warrants and represents to the other Party on the Effective Date that:

 

(a)          Authority.
It has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit
its ability to perform the obligations imposed on it by this Agreement.

 

(b)          Corporate
Action. All corporate action on the part of such Party, its officers, directors and stockholders necessary for (i) the authorization,
execution and delivery of this Agreement and (ii) the performance of all obligations of such Party hereunder has been taken, and
this Agreement constitutes the legal and binding obligation of such Party, enforceable against such Party in accordance with its
terms.

 

(c)          Execution.
The execution of this Agreement and the performance of the transactions contemplated by this Agreement by such Party will not conflict
with or result in a breach of any of the terms, conditions or provisions of, or constitute a default under any agreement or other
instrument to which such Party is a party or by which it or any of its property is bound.

 

    	23

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

13.2         Additional
Representations of Advaxis. In addition, Advaxis warrants and represents to Licensee on the Effective Date that:

 

(a)          No
Inconsistent Grants. There is no Third Party license agreement in effect as of the Effective Date which is inconsistent with
the rights and licenses granted to Licensee under Article 2. With respect to any technology or product Advaxis may develop with
its Affiliates or any Third Party after the Effective Date, Advaxis and its Affiliates will not enter into any agreement or act
in any way contrary to or inconsistent with Licensee’s exclusive right (even as to Advaxis or its Affiliates) to Develop,
manufacture, have manufactured, import, use and Commercialize Products in the Territory.

 

(b)          Authority
to Grant License. Advaxis has the full right, power and authority to grant, has been granted any required consents, and is
not prohibited by the terms of any agreement to which it is a party from granting, the licenses granted to Licensee under Article
2.

 

(c)          Confidentiality.
To Advaxis’s knowledge, the material know-how within the Licensed Technology existing at the Effective Date has been kept
confidential or has been disclosed to Third Parties only under terms of confidentiality, except where the failure to keep such
know-how confidential will not have a material effect on Development or Commercialization of Products in the Territory in the Field.

 

(d)          Development
and Manufacture In Compliance With Laws. The Development and manufacture of Products have been conducted by Advaxis and its
Affiliates and, to Advaxis’s knowledge, its subcontractors, in compliance (in all material respects) with all applicable
laws. Neither Advaxis nor its Affiliates, nor to Advaxis’s knowledge, its subcontractors, have received any notice in writing
that any of the regulatory authorizations relating to any Product are not currently in good standing with any governmental authority.
Except as would not have a material adverse effect on the Product or Licensee’s rights under this Agreement, neither Advaxis
nor its Affiliates has knowledge of any facts, which have, or reasonably should have, led Advaxis to believe that any of the regulatory
authorizations relating to the Product are not currently in good standing with any governmental authority.

 

(e)          Testing.
Except as would not have a material adverse effect on the Products or Licensee’s rights under this Agreement, all testing,
research and development by Advaxis and its Affiliates have been conducted in compliance with cGCP and/or cGLP and/or cGMP, as
applicable, and required at the time such activity was performed.

 

(f)          Regulatory
Authority. Except as would not have a material adverse effect on the Products or Licensee’s rights under this Agreement,
there are no inquiries, actions or other proceedings pending before or, to Advaxis’s knowledge, threatened by any governmental
authority with respect to Products, and neither Advaxis nor its Affiliates has received written notice threatening any such inquiry,
action or other proceeding.

 

    	24

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

(g)          Documents
Have Been Provided. Advaxis has, up to and including the Effective Date, made available for Licensee’s review, to the
extent in Advaxis’s possession, (a) for the prior two years, other documents that assert ongoing lack of compliance in any
material respect with any applicable laws, in each case, to the extent received by Advaxis or any of its Affiliates and relating
to Products, (b) preclinical and clinical study reports for Products, (c) any material communications to or from any governmental
authority with respect to Products, IND submissions, and any minutes of meetings and telephone conferences, (d) any governmental
authority requests for data and studies on Products, and (e) safety reports with respect to Products, that are material to assessing
Advaxis’s or any of its Affiliates’ compliance with the Federal Food, Drug and Cosmetic Act. Advaxis has not, up through
and including the Effective Date, withheld from or omitted to provide or make available any material information to Licensee
requested by Licensee in connection with Licensee’s due diligence relating to the Product, Licensed Technology, this
Agreement and the underlying transaction contemplated hereby.  To
the best of Advaxis’s knowledge, information related to Products and Licensed Technology that Advaxis has provided, or made
available, to Licensee in connection with Licensee’s due diligence prior to the Effective Date is complete and accurate in
all material respects.

 

(h)          Intellectual
Property.

 

(i)          Schedule
1.27 sets forth a list of all Patent Rights.

 

(ii)         Advaxis
has been assigned and owns all right, title and interest of each inventor listed for each item listed on Schedule 1.27, free and
clear of liens.

 

(iii)        All
former and current employees of Advaxis have executed written agreements prohibiting disclosure of confidential information and
assigning to Advaxis, all rights to any inventions relating to Licensed Technology made during their employment with Advaxis.

 

(iv)        Advaxis
has taken commercially reasonable precautions to protect the secrecy of its trade secrets.

 

(v)         Advaxis
has not been alleged to infringe any intellectual property right of any Third Party and there is no claim or action pending or,
to Advaxis’s knowledge, threatened, alleging any such infringement.

 

(vi)        To
Advaxis’s knowledge, the making, using or selling of the Product or the Lm-LLO Immunotherapies Composition does not
infringe any valid claim in a granted patent owned by a Third Party.

 

(vii)       (a)
Advaxis is not aware of any Third Party, or any Advaxis (or any of its Affiliate’s) employee that has any claim of ownership
with respect to Licensed Technology existing as of the Effective Date; (b) with regard to the Licensed Technology existing as of
the Effective Date, no Third Party claim contesting the validity, enforceability, use or ownership of the Licensed Technology has
been made (or threatened in writing) and is currently outstanding; (c) Advaxis has not received any notices of, nor is it aware
of any facts which would indicate a reasonable likelihood of, any infringement or misappropriation by any Third Party of the Patent
Rights existing as of the Effective Date; and (d) Advaxis has not received any notices, demands or requests that, and Advaxis has
not engaged in any discussions with any Third Party that, Advaxis license rights to any intellectual property owned or controlled
by any Third Party relating to the making, using or selling of the Product or the Lm-LLO Immunotherapies Composition.

 

    	25

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

13.3         Additional
Representation of Licensee. In addition, Licensee warrants and represents to Advaxis that:

 

(a)          
Prior to the Effective Date, Licensee has conducted due diligence and has reviewed all documents relating to the Products, Licensed
Technology, and other information related to the transaction set forth in this Agreement and the underlying transaction hereby
as has been provided or made available to Licensee by Advaxis.

 

(b)          Licensee
is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities
Act of 1933, as amended). Licensee is capable of evaluating the merits and risks of its investment in Advaxis and has the capacity
to protect its interests. Licensee understands that it may have to bear the economic risk of an investment in the Purchased Shares
for an indefinite period of time. Licensee hereby confirms that the Purchased Shares are being acquired for investment for the
Licensee’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof.

 

13.4         Disclaimer
of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN ARTICLE 13, NEITHER PARTY MAKES ANY REPRESENTATIONS AND GRANTS
NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY
DISCLAIMS ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY
OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENT RIGHTS
OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE
14

INDEMNIFICATION

 

14.1         By
Advaxis. Advaxis shall defend, indemnify and hold harmless Licensee and its Affiliates and each of their officers, directors,
shareholders, employees, successors and assigns (collectively, “Licensee Indemnitees”) from and against all
claims, charges, complaints, actions, suits, proceedings, hearings, investigations and demands (“Claims”) of
Third Parties (including licensors and licensees of Advaxis) and Advaxis’s Affiliates, and all associated Losses (including
attorneys’ fees incurred by Licensee and its Affiliates), to the extent arising out of (a) the Development, use, manufacture
or Commercialization of Products inside the Territory by or under authority of Advaxis (including by Licensee, its Affiliates or
sublicensees pursuant to the licenses granted hereunder) and to the extent such Claims allege that the use of Licensed Technology
infringes any intellectual property right of any Third Party or Affiliate of Advaxis, (b) the Development, use, manufacture or
Commercialization by or under authority of Advaxis (other than by Licensee, its Affiliates or sublicensees pursuant to the licenses
granted hereunder) of any products with respect to which Advaxis has exercised any rights under Section 5.3(a), (c) any breach
by Advaxis of any representation, warranty, covenant or obligation given in this Agreement, or (d) the gross negligence or willful
misconduct of Advaxis in the performance of its obligations hereunder; provided, however, that in all cases referred to in this
Section 14.1, Advaxis shall not be liable to indemnify any Licensee Indemnitee for any Losses to the extent that Licensee is obligated
to indemnify an Advaxis Indemnitee for such Losses pursuant to Section 14.2. Upon Licensee’s request, Advaxis shall provide
information and documents related to the defense of Claims.

 

    	26

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

14.2         By
Licensee. Licensee shall defend, indemnify and hold harmless Advaxis and its Affiliates and each of their officers, directors,
shareholders, employees, successors and assigns (collectively, “Advaxis Indemnitees”) from and against all Claims
of Third Parties, and all associated Losses, to the extent arising out of (a) the Development, use, manufacture or Commercialization
of Products in the Territory, (b) the Development, use or manufacture by Licensee or its Affiliates or permitted sublicensees of
Products outside the Territory, (c) any breach by Licensee or any of its Affiliates of any representation or warranty, covenant,
or obligation given in this Agreement or (d) the gross negligence or willful misconduct of Licensee or any of its Affiliates in
the performance of its obligations hereunder; provided, however, that in all cases referred to in this Section 14.2, Licensee shall
not be liable to indemnify any Advaxis Indemnitee for any Losses to the extent that Advaxis is obligated to indemnify a Licensee
Indemnitee for such Losses pursuant to Section 14.1.

 

14.3         Procedure
for Indemnification.

 

(a)          Notice.
Each Party will notify promptly the other if it becomes aware of a Claim (actual or potential) by any Third Party (a “Third
Party Claim”) for which indemnification may be sought by that Party and will give such information with respect thereto
as the other Party shall reasonably request. If any proceeding (including any governmental investigation) is instituted involving
any Party for which such Party may seek an indemnity under Section 14.1 or Section 14.2 (the “Indemnified Party”),
the Indemnified Party shall not make any admission or statement concerning such Third Party Claim, but shall promptly notify the
other Party (the “Indemnifying Party”) orally and in writing and the Indemnifying Party and Indemnified Party
shall meet to discuss how to respond to any Third Party Claims that are the subject matter of such proceeding. The Indemnifying
Party shall not be obligated to indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified
Party or any failure by such Party to notify the Indemnifying Party of the Claim materially prejudices the defense of such Claim.

 

    	27

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

(b)          Defense
of Claim. The following provisions shall apply to any Claim to which a Party is entitled to indemnification from the other
Party under this Article 14. If the Indemnifying Party elects to defend or, if local procedural rules or laws do not permit the
same, elects to control the defense of a Third Party Claim, it shall be entitled to do so provided it gives notice to the Indemnified
Party of its intention to do so within forty-five (45) days after the receipt of the written notice from the Indemnified Party
of the potentially indemnifiable Third Party Claim (the “Litigation Condition”). Subject to compliance with
the Litigation Condition, the Indemnifying Party shall retain counsel reasonably acceptable to the Indemnified Party (such acceptance
not to be unreasonably withheld, refused, conditioned or delayed) to represent the Indemnified Party and shall pay the fees and
expenses of such counsel related to such proceeding. In any such proceeding, the Indemnified Party shall have the right to retain
its own counsel, but the fees and expenses of such counsel shall be at the expense of the Indemnified Party. The Indemnified Party
shall not settle any Claim for which it is seeking indemnification without the prior consent of the Indemnifying Party which consent
shall not be unreasonably withheld, refused, conditioned or delayed. The Indemnified Party shall, if requested by the Indemnifying
Party, cooperate in all reasonable respects in the defense of such Claim that is being managed and/or controlled by the Indemnifying
Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably
withheld, refused, conditioned or delayed), effect any settlement of any pending or threatened proceeding in which the Indemnified
Party is, or based on the same set of facts could have been, a party and indemnity could have been sought hereunder by the Indemnified
Party, unless such settlement includes an unconditional release of the Indemnified Party from all liability on Claims that are
the subject matter of such proceeding. If the Litigation Condition is not met, then neither Party shall have the right to control
the defense of such Third Party Claim and the Parties shall cooperate in and be consulted on the material aspects of such defense
at each Party’s own expense; provided that if the Indemnifying Party does not satisfy the Litigation Condition, the Indemnifying
Party may at any subsequent time during the pendency of the relevant Third Party Claim irrevocably elect, if permitted by local
procedural rules or laws, to defend and/or to control the defense of the relevant Third Party Claim so long as the Indemnifying
Party also agrees to pay the reasonable fees and costs incurred by the Indemnified Party in relation to the defense of such Third
Party Claim from the inception of the Third Party Claim until the date the Indemnifying Party assumes the defense or control thereof.

 

14.4         Assumption
of Defense. Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the
defense of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party pursuant
to this Section 14.4, in which case the Indemnifying Party shall be relieved of liability under Section 14.1 or Section 14.2, as
applicable, solely for such Third Party Claim and related Losses.

 

14.5         No
Consequential or Punitive Damages. Neither Party hereto will be liable for indirect, incidental, consequential, special, exemplary,
punitive or multiple damages arising out of this Agreement or the exercise of its rights hereunder, or for lost profits arising
from or relating to any breach of this Agreement, regardless of any notice of such damages. Nothing in this Section 14.5 is intended
to limit or restrict the indemnification rights or obligations of either Party pursuant to Sections 14.1 and 14.2 with respect
to Third Party Claims.

 

    	28

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

ARTICLE
15

INSURANCE

 

15.1        Insurance.
Each Party shall maintain product liability insurance for clinical trials performed by such Party pursuant to this Agreement and
Licensee shall also maintain product liability insurance for commercial sales of Products pursuant to this Agreement, in each case
to support the indemnity provided to the other Party pursuant to this Agreement, in such amounts customarily maintained with respect
to its other products and which is reasonable and customary in the pharmaceutical industry for companies of comparable size and
activities. Such insurance policies shall remain in effect throughout the Term and for the period of time for which either Party
has indemnification obligations following termination of this Agreement and shall not be cancelled or subject to a reduction of
coverage without the prior written authorization of the other Party. Upon request by the other Party, a Party shall furnish certificates
of insurance for all of the above noted policies. Each insurance policy that is required under this Section shall be obtained from
an insurance carrier with an A.M. Best rating of at least A-VII.

 

ARTICLE
16

TERM AND TERMINATION

 

16.1        Term.
The Term shall commence on the Effective Date and expire, unless earlier terminated upon the mutual written agreement of the Parties
or in accordance with the provisions of this Article 16, on the date of expiration of all royalty and other payment obligations
(the “Expiration Date”) under this Agreement.

 

16.2        Termination
for Breach or Bankruptcy.

 

(a)          Each
Party (the “Non-Breaching Party”) shall be entitled to terminate this Agreement in its entirety or on a Product-by-Product,
country-by-country basis, by written notice to the other Party (the “Breaching Party”) in the event that the
Breaching Party is materially in default of any of its material obligations hereunder or, in the case of a termination on a Product-by-Product,
country-by-country basis, relating to such Product and such country, and fails to remedy such default within sixty (60) days (or,
in the case of payment defaults, within thirty (30) days) after provision of written notice thereof by the Non-Breaching Party
identifying the alleged breach in reasonable detail.

 

(b)          The
effective date of termination of this Agreement under this Section 16.2 for an unremedied material breach of a material obligation
shall be the date sixty (60) days (or, in the case of an unremedied payment default, thirty (30) days) after provision of written
notice thereof by the Non-Breaching Party.

 

(c)          This
Agreement may be terminated by a Party upon written notice to the other (i) in the event that the other Party shall make an assignment
for the benefit of its creditors, file a petition in bankruptcy, petition or apply to any tribunal for the appointment of custodian,
receiver or any trustee for it or a substantial part of its assets, or shall commence any proceeding under any bankruptcy, reorganization,
arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction, whether now or hereafter in effect;
or (ii) if there shall have been filed against the other Party any such bona fide petition or application, or any such proceeding
shall have been commenced against it, in which an order for relief is entered or which remains undismissed for a period of ninety
(90) days or more; or (iii) if the other Party by any act or omission shall indicate its consent to, approval of or acquiescence
in any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or trustee for
it or any substantial part of its assets, or shall suffer any such custodianship, receivership or trusteeship to continue undischarged
for a period of ninety (90) days or more; or (iv) if anything analogous to any of the foregoing occurs in any applicable jurisdiction.
Termination shall be effective upon the date specified in such notice. For the avoidance of doubt, the Party with the right to
terminate under this Section 16.2(c) is the Party not experiencing the events described in the foregoing clauses (i), (ii), (iii)
and (iv).

 

    	29

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

(d)          In
lieu of termination of this Agreement, in the event that (i) Advaxis shall make an assignment for the benefit of its creditors,
file a petition in bankruptcy, petition or apply to any tribunal for the appointment of custodian, receiver or any trustee for
it or a substantial part of its assets, or shall commence any proceeding under any bankruptcy, reorganization, arrangement, readjustment
of debt, dissolution or liquidation law or statute of any jurisdiction, whether now or hereafter in effect; or (ii) if there shall
have been filed against Advaxis any such bona fide petition or application, or any such proceeding shall have been commenced against
it, in which an order for relief is entered or which remains undismissed for a period of ninety (90) days or more; or (iii) if
Advaxis by any act or omission shall indicate its consent to, approval of or acquiescence in any such petition, application or
proceeding or order for relief or the appointment of a custodian, receiver or trustee for it or any substantial part of its assets,
or shall suffer any such custodianship, receivership or trusteeship to continue undischarged for a period of ninety (90) days or
more; or (iv) anything analogous to any of the foregoing occurs in any applicable jurisdiction, then the Parties shall have all
rights and obligations as provided in Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) with respect
to license rights. The Parties agree that any licenses or rights granted under or pursuant to this Agreement by Advaxis to Licensee
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual
property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that during the Term, Licensee, as
a licensee of rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy
Code, subject to the continued performance of its obligations under this Agreement.

 

16.3         Patent
Challenge. Advaxis will be permitted to terminate this Agreement by written notice effective upon receipt if Licensee or its
Affiliates (other than an Affiliate conducting such action prior to a Change of Control of such Affiliate), directly or indirectly
through assistance granted to a Third Party, commence any interference or opposition proceeding, challenge the validity or enforceability
of, or oppose any extension of or the grant of a supplementary protection certificate with respect to, any Patent Rights (each
such action, a “Patent Challenge”). Licensee will include provisions in all agreements granting sublicenses
of Licensee’s rights hereunder providing that if the sublicensee or its Affiliates undertake a Patent Challenge with respect
to any Patent Rights under which the sublicensee is sublicensed, Licensee will be permitted to terminate such sublicense agreement.
If a sublicensee of Licensee (or an Affiliate of such sublicensee) undertakes a Patent Challenge of any such Patent Right under
which such sublicensee is sublicensed, then Licensee upon receipt of notice from Advaxis of such Patent Challenge will terminate
the applicable sublicense agreement. If Licensee fails to so terminate such sublicense agreement, Advaxis may terminate Licensee’s
right to sublicense in the countr(ies) covered by such sublicense agreement and any sublicenses previously granted in such countr(ies)
shall automatically terminate. In connection with such sublicense termination, Licensee shall cooperate with Advaxis’s reasonable
requests to cause such a terminated sublicensee to discontinue activities with respect to the Product in such countr(ies).

 

    	30

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

16.4        Consequences
of Termination.

 

(a)          Expiration.
Upon the Expiration Date, the licenses granted to Licensee by Advaxis shall become fully paid-up and irrevocable, subject to any
obligations which have accrued prior to the Expiration Date.

 

(b)          Termination
by either Party under Section 16.2. In the event this Agreement is terminated in its entirety by either Party under Section
16.2, then, notwithstanding Section 16.6, any and all rights, obligations and covenants of the Parties set forth in Article 11
(except for Sections 11.1(a), (b)) shall terminate in their entirety.

 

(c)          Termination
by Licensee or by Advaxis for Breach or Bankruptcy or a Patent Challenge. Upon any termination of this Agreement by Licensee
pursuant to Section 16.2 or by Advaxis pursuant to Section 16.3:

 

(i)          Any
and all licenses granted by Advaxis to Licensee under this Agreement shall terminate in their entirety or with respect to the Product(s)
and country(ies) to which the termination relates, as the case may be, on the effective date of such termination

 

(ii)         Upon
either Party’s written request, the Parties may promptly commence and diligently undertake good faith negotiations, in an
effort to reach mutually acceptable terms for the assignment and transfer to the other Party or its Affiliates, and free of any
liens, pledges, security interests and other financial encumbrances including those incurred in the Commercialization of the Product,
all of a Party’s right, title and interest in and to the trademarks (including any goodwill associated therewith) which are
solely used in connection with Commercialization of Product(s) (for the avoidance of doubt, excluding housemark as well as any
other trademarks used in connection with any other product(s) or in connection with the business in the Field generally), any registrations
and design patents for any of the foregoing and any internet domain name registrations for such trademarks and slogans, all regulatory
filings (such as INDs and NDAs), other Regulatory Approvals, and clinical trial agreements (to the extent assignable and not cancelled)
for such Product(s) in such country(ies), and all data, including clinical data, materials and information of any kind or nature
whatsoever, in a Party’s possession or in the possession of its Affiliates or its or their respective agents related to such
Product(s) in such country(ies) developed under this Agreement. All such filings, approvals and data transferred to the other Party
pursuant to this Section 16.4 shall be deemed to be the transferee’s Confidential Information;

 

(iii)        If
Licensee is responsible for the commercial supply of Product at the time of termination, then Licensee shall supply, or cause to
be supplied, to Advaxis, upon Advaxis’s written request, Advaxis’s or its licensee’s commercial requirements
of Product, pursuant to a supply agreement to be negotiated in good faith by the Parties on commercially reasonable terms, provided
that (1) any and all or part of Licensee’s remaining supply and inventory of Product shall be provided to and paid by Advaxis
at Licensee’s fully burdened cost of goods plus twenty percent (20%), (2) any additional requirements for Product shall be
supplied to and paid by Advaxis or its licensee at Licensee’s fully burdened cost of goods plus twenty percent (20%), (3)
Licensee’s supply obligation shall not continue for more than twenty-four (24) months after the termination of this Agreement,
(4) Licensee shall maintain the same quality and specifications for manufacturing Product as immediately prior to notice of termination,
and (5) Advaxis shall effect a transfer as soon as practicable of Product manufacturing activities from Licensee to another supplier.
Licensee shall also provide Advaxis or its designated supplier, at Advaxis’s cost, reasonable assistance and cooperation
in providing a manufacturing transfer package with the goal of enabling Advaxis or such designated supplier to manufacture the
Product; and

 

    	31

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

(iv)        Other
than in Section 16.4(c)(iii) above, Licensee shall cease Developing, manufacturing, and Commercializing such Products under this
Agreement and the licenses granted to Licensee hereunder with respect to such Products shall terminate.

 

(d)          Termination
due to Advaxis’s Breach or Bankruptcy. Upon any termination of this Agreement by Licensee with respect to a Product or
country under Section 16.2(a) or termination of this Agreement in its entirety by Licensee pursuant to Sections 16.2(a) or 16.2(c),
any and all licenses granted by Advaxis to Licensee under this Agreement shall terminate in their entirety or with respect to the
Product(s) and country(ies) to which the termination relates, as the case may be, on the effective date of such termination.

 

(e)          Royalty
and Payment Obligations. Termination of this Agreement by either Party for any reason will not release Licensee from any obligation
to pay royalties or milestones or to make any payments to Advaxis which were accrued prior to the effective date of termination
(including for milestone events achieved under Article 8, prior to the date of termination) or that relate to Product(s) or country/countries
to which such termination does not relate. However, termination of this Agreement by either Party for any reason will release Licensee
from any obligation to pay royalties or make any payments to Advaxis which would have otherwise become accrued after the effective
date of termination (provided that Licensee shall be obligated to pay royalties after the effective date of termination for Products
sold prior to such effective date).

 

16.5         Non-Exclusive
Remedy for Breach. The provisions of Section 16.4 are not intended to be exclusive and are without prejudice to the rights
of the Parties to seek any other rights and remedies that they may have under this Agreement, at law or in equity or otherwise.

 

16.6         Survival
of Obligations. Subject to Section 16.4(b), Sections 11.1, 11.2, 13.1 (for the periods of time set forth therein), 13.2, 13.3,
13.4 and Articles 10, 12, 14 and 17 and any definitions used in any such Section or Article shall survive the termination of this
Agreement in its entirety. Except for obligations which clearly are not intended to continue in respect of a partial termination
pursuant to Section 16 (including the applicable diligence obligation), with respect to the country or Product terminated, all
obligations in this Agreement shall survive such partial termination.

 

    	32

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

ARTICLE
17

MISCELLANEOUS

 

17.1         Dispute
Resolution and Governing Law. The Parties shall attempt in good faith to resolve any dispute relating to or arising out of
this Agreement through face-to-face negotiations between senior executives of each Party. If the dispute is not resolved within
thirty (30) days of commencing such face-to-face negotiations, or if the Party against which a claim has been asserted refuses
to attend such negotiations or does not otherwise participate in such negotiations within thirty (30) days from the date of its
receipt of notice of a dispute, then the Parties agree that any such dispute shall be submitted to any U.S. federal or New York
State court of competent jurisdiction sitting in the Borough of Manhattan in the City and State of New York. This Agreement shall
be governed by the laws of the State of New York without regard to its conflict of laws rules or principles.

 

17.2         Compliance
with Law. Each Party hereby covenants and agrees to comply in all material respects with all laws and regulations applicable
to its activities in connection with the Development, supply and Commercialization of the Products, including the requirements
of the PDM Act, and any import and export laws and regulations.

 

17.3         Force
Majeure. Neither Party shall be responsible to the other Party for nonperformance or delay in performance of the terms or conditions
of this Agreement due to acts of God, acts of governments, war (declared or undeclared), acts of terrorism, riots, strikes, accidents
in transportation, or other causes beyond the reasonable control of such Party, but such force majeure shall toll any and all obligations
(other than payment obligations) and time periods for so long as such force majeure continues. Upon the occurrence of an event
of force majeure, the Party whose performance is affected thereby shall notify the other Party promptly of such event. Upon the
cessation of such event, such Party shall take all reasonable steps within its power to resume with the least possible delay compliance
with its obligations hereunder.

 

17.4         Waiver.
The waiver by a Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as
a waiver of any subsequent breach of the same or any other provision hereof, nor shall any delay or omission on the part of a Party
to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of that or any
other right, power or privilege of such Party hereunder.

 

17.5         Notices.
Any notice or other communication required or permitted to be given in connection with this Agreement must be in writing and may
be given by any of the following methods: (i) personal delivery with a signed acknowledgement of receipt; (ii) registered or certified
mail, postage prepaid, return receipt requested; or (iii) by overnight delivery service with a signed acknowledgement of receipt.
Notice shall be effective when delivered to the addressee at the address listed below or such other address as the addressee shall
have specified in a written notice actually received by the addresser.

 

    	33

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

If to Advaxis:

 

305 College Road East

Princeton, New Jersey 08540

Attn: Daniel J. O’Connor

 

If to Licensee:

 

6F, No.10, LinSen S. Road

Taipei City, Taiwan, R.O.C.

Attn: HunChi Lin

 

17.6         Relationship
of the Parties. The Parties are independent contractors. Nothing herein is intended, or shall be deemed, to constitute a partnership,
agency, joint venture or employment relationship between the Parties. Neither Party shall be responsible for the other Party’s
acts or omissions; and neither Party shall have authority to speak for, represent or obligate the other Party in any way without
prior written authority from the other Party. Subject to the terms of this Agreement, the activities and resources of each Party
shall be managed by such Party, acting independently and in its individual capacity.

 

17.7         Entire
Agreement. This Agreement and the Schedules attached hereto (which Schedules are incorporated herein by reference and are deemed
to be a part of this Agreement for all purposes) constitute the entire agreement of the Parties with respect to the subject matter
hereof and supersede all prior understandings and writings between the Parties relating thereto. No amendment, waiver, alteration
or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by the Parties.

 

17.8         Headings.
The headings contained in this Agreement are for convenience of reference only and shall not be considered in interpreting this
Agreement.

 

17.9         Severability.
In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is
invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions of this Agreement shall
not be affected thereby, and the Parties shall negotiate a substitute provision that, to the extent possible, accomplishes the
original business purpose of the unenforceable provision. During the period of such negotiation, and thereafter if no substituted
provision is agreed upon in writing by the Parties, any such provision which is enforceable in part but not in whole shall be enforced
to the maximum extent permitted by law.

 

    	34

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

17.10        Assignment
and Transfer. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by either
Party without the prior written consent of the other Party, except each Party may, without consent of the other Party, assign or
otherwise transfer this Agreement and its rights and obligations hereunder in whole or in part: (a) to any Affiliate; (b) in connection
with a Change of Control; or (c) in connection with any Sale of the Field Business; or (d) to any Third Party in connection with
a transaction in which such Party acquires control of another Third Party or any of its products, assets or businesses (whether
by license, asset or company acquisition, merger, joint venture, partnership or other business transaction or combination), where
in such transaction HPV-related product(s) represent less than fifty percent (50%) of the net present value of such transaction
(as set forth in such Party's final presentation to its board of directors seeking corporate approval for such transaction), and
where the Federal Trade Commission or Department of Justice of the United States requires such Party to divest the Products that
are the subject matter of this Agreement and only the Products. Any attempted assignment or other transfer not in accordance with
this Section 17.10 shall be void. Any permitted assignee shall assume in writing all assigned obligations of its assignor under
this Agreement. The Party making any assignment or other transfer permitted under this Section 17.10 shall provide prompt written
notice to the other Party of such assignment or transfer. Notwithstanding any provision herein to the contrary, Advaxis shall be
entitled to assign its rights to receive payments under this Agreement to a Third Party and Licensee shall be entitled to assign
its rights under this Agreement as security to any financial institution providing financing to Licensee, pursuant to the terms
of the relevant security agreement; provided, further, that any permitted assignment shall protect Advaxis’s rights under
this Agreement.

 

17.11      Successors
and Assigns. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their successors and permitted assigns.

 

17.12      Interpretation.

 

(a)          General.
Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; and (b) words using
the singular or plural number also include the plural or singular number, respectively. Whenever this Agreement refers to a number
of days, unless otherwise specified, such number shall refer to calendar days.

 

(b)          Other
Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement,
contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof
and thereof.

 

(c)          Capitalization.
Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein, shall have the meaning as defined in this
Agreement.

 

(d)          Date
References. References from or through any date mean, unless otherwise specified, from and including or through and including,
respectively.

 

(e)          Schedules.
All Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth
in full herein.

 

(f)          References.
References to any entity include the successors and permitted assigns of that entity.

 

(g)          References
to Parts of this Agreement. References to Articles, Sections, and Schedules are to Articles, Sections and Schedules of this
Agreement unless otherwise specified.

 

    	35

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

(h)          Other
Definitional and Interpretative Provisions. The words “hereof”, “herein” and “hereunder”
and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of
this Agreement. Whenever the words “include”, “includes” or “including” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by
those words or words of like import. “Writing”, “written” and comparable terms refer to printing, typing
and other means of reproducing words (including electronic media) in a visible form. The word “will” shall be construed
to have the same meaning and effect as the word “shall.” The word “or” shall be construed to have the same
meaning and effect as “and/or.”

 

17.13       Counterparts.
This Agreement may be executed manually, electronically in Adobe PDF file format, or by facsimile by the Parties, in any number
of counterparts, each of which shall be considered one and the same agreement and shall become effective when a counterpart hereof
shall have been signed by each of the Parties and delivered to the other Party.

 

17.14       Further
Actions. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and
do and cause to be done such further acts and things, as may be necessary or as the other Party may reasonably request in connection
with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other
Party its rights under this Agreement, including executing and delivering appropriate assignment and assumption agreements and
bill of sale documentation in connection with the transfer of ownership for NDA, copyright rights, domain names and regulatory
filings which are to be transferred hereunder.

 

[Signature Page
Follows] 

 

    	36

    	 

    

 

Exhibit 10.79

 

Note: Portions of this document have been marked “[c.i.]”
to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions
have been submitted separately with the Securities and Exchange Commission.

 

IN WITNESS WHEREOF, the Parties hereto have
caused this Agreement to be executed in their names by their properly and duly authorized officers or representatives as of the
date first written above.

 

	 	Advaxis Inc.
	 	 	 
	 	By:	/s/  Daniel J. O’Connor
	 	Name:	Daniel J. O’Connor
	 	Title:	Chief Executive Officer
	 	 	 
	 	Global BioPharma, Inc.
	 	 	 
	 	By:	/s/  George Ko
	 	Name:	George Ko
	 	Title:	Chairman

 

[Signature
Page to License, Development and Commercialization Agreement] 

 

    	 

    	 

    

 

Exhibit 10.79

 

Note: Portions of this document have been marked “[c.i.]”
to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions
have been submitted separately with the Securities and Exchange Commission.

 

SCHEDULE 1.27

 

Issued Patent

 

	Application No. /

Publication No. /

Registration No.	 	Country	 	Filing Date	 	Title
	
        1996-515534

         
	 	Japan	 	
        03-Nov-95

         
	 	SPECIFIC IMMUNOTHERAPY OF CANCER USING A LIVE RECOMBINANT BACTERIAL VACCINE VECTOR

 

Pending Patent Applications

 

	Application No. /

Publication No. /

Registration No.	 	Country	 	Filing Date	 	Title
	
        2013-219162
	 	Japan	 	
        12-May-08
		COMPOSITIONS AND METHODS COMPRISING KLK3, PSCA, OR FOLH1 ANTIGEN
	
        2009-552749
		Japan		
        07-Mar-08
		COMPOSITIONS AND METHODS FOR TREATMENT OF CERVICAL CANCER
	
        2007-525861
	 	Japan	 	
        15-Aug-05
	 	METHODS FOR CONSTRUCTING ANTIBIOTIC RESISTANCE FREE VACCINES
	201180057899.5	 	China	 	
        03-Oct-11
		THE USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE UNRESPONSIVENESS IN PARASITICALLY INFECTED INDIVIDUALS
	2013-531954	 	Japan	 	
        03-Oct-11

         
	 	THE USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE UNRESPONSIVENESS IN PARASITICALLY INFECTED INDIVIDUALS
	2011-510653	 	Japan	 	
        19-May-09
		DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS
	2012-539021	 	Japan	 	
        12-Nov-10

         
	 	COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
	102129605	 	Taiwan	 	
        16-Aug-13

         
	 	COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS

 

    	 

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

 

	Not yet known	 	China	 	
        12-Mar-12
	 	LISTERIA-BASED ADJUVANTS
	
        2011-553117
	 	Japan	 	
        04-Mar-10
	 	COMPOSITIONS COMPRISING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
	
        2011-516486
	 	Japan	 	
        22-Jun-09
		NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME
	PCT/US13/30521	 	PCT	 	12-Mar-13	 	SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING LISTERIA VACCINE TREATMENT
	PCT/US12/51187	 	PCT	 	16-Aug-12	 	COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS

 

    	 

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

   

SCHEDULE 1.34

 

		l	All countries and territories in the continent of Africa except for Algeria, Egypt, Eritrea, Kenya, Libya, Morocco, Sudan,
Tunisia, and Western Sahara

 

		l	All countries and territories in the continent of Asia except for Armenia, Bahrain, Bangladesh, Bhutan, Burma, India, Iran,
Iraq, Jordan, Kuwait, Lebanon, Malaysia, Maldives, Nepal, Oman, Pakistan, Qatar, Saudi Arabia, Sri Lanka, Syria, United Arab Emirates
and Yemen.

 

		l	Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan,
Ukraine, Uzbekistan

 

    	 

    	Note: Portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for certain redacted confidential information. The confidential portions have been submitted separately with the Securities and Exchange Commission.

    

  

SCHEDULE 8.3

 

Milestone Events and Payments

 

	Milestone

Number	 	Milestone Event	 	Payment

Amount
	1	 	Completion of technical transfer by Advaxis to Licensee of all Licensed Technology which enables the manufacture of the Product using a drying method, provided that Licensee has provided prior written request for such technical transfer.  Such transfer shall occur as soon as reasonably practicable following the Effective Date, however, the milestone payment shall not be due until the later of (i) the completion of the transfer and (ii) two years and six months after the Effective Date.	 	[c.i.]
	2	 	First Regulatory Approval for each and any indication in the Territory.  To avoid any doubt, Licensee shall not be obligated to pay for the Regulatory Approval of an indication if a prior Regulatory Approval has been obtained for the same indication in another country within the Territory.  All uses for the prevention or treatment of the same disease shall be counted as one indication, regardless of the stage or severity of the disease, for the purpose of determining the milestone payment due under this Schedule.  For instance, the treatment of cervical cancer in an advanced stage and the treatment of cervical cancer in an early stage shall be counted as only one indication.	 	[c.i.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]